Introduction {#s1}
============

Diabetes is a major risk factor contributing to cardiovascular complications, including hypertension, increased risk of stroke, coronary disease, and organ failure ([@bib81]). These complications are often linked to the effects of elevated extracellular glucose (e.g. hyperglycemia - the hallmark metabolic abnormality in diabetes) on vascular function ([@bib11]; [@bib16]; [@bib79]). In addition to endothelium-dependent alterations ([@bib46]; [@bib76]), endothelium-independent modifications, including enhanced contractility of arterial myocytes, are emerging as critical contributing factors to these complications ([@bib4]; [@bib21]; [@bib29]; [@bib54]; [@bib63]). Consistent with this notion, we and others recently demonstrated augmented vasoconstriction in response to acute and chronic elevations in extracellular glucose that were independent of endothelial function ([@bib29]; [@bib40]; [@bib68]). We linked these glucose-mediated effects on vascular reactivity to an increase in L-type Ca~V~1.2 channel (LTCC) activity in human and murine arterial myocytes ([@bib60]; [@bib68]). This is critical, as Ca^2+^ influx via LTCCs is the main Ca^2+^ entry pathway in these cells and determines muscle contractility and arterial diameter ([@bib45]). Unexpectedly, we found that glucose-mediated potentiation of LTCCs involves phosphorylation of Ca~V~1.2 at serine 1928 (Ser^1928^) by protein kinase A (PKA) ([@bib56]; [@bib60]; [@bib68]). Yet, how glucose leads to PKA activation is unknown.

Elevations in cellular glucose have been shown to trigger autocrine release of nucleotides (e.g. ATP, UTP) into the extracellular space of many cells, including arterial myocytes ([@bib17]; [@bib37]; [@bib64]; [@bib69]). These extracellular nucleotides can then act on G protein-coupled P2Y receptors to induce a plethora of cellular responses ([@bib80]). Previous studies demonstrated that elevations in extracellular glucose led to increases in intracellular Ca^2+^ (\[Ca^2+^\]~i~) in isolated arterial myocytes ([@bib64]). Indeed, this glucose-mediated response was associated with enhanced autocrine release of nucleotides engaging P2Y receptors, but the contributing mechanisms as well as the identity of the P2Y receptor involved are unclear.

Eight functionally diverse G protein-coupled P2Y receptors have been identified ([@bib80]). Most of these P2Y receptors are coupled to G~q/i~ proteins. Conversely, P2Y~11~ is the only P2Y receptor that is coupled to G~s~ ([@bib14]; [@bib42]; [@bib75]; [@bib80]). Activation of this receptor could then activate adenylyl cyclase (AC) and PKA to underlie the glucose-induced effects on LTCC activity, but its role in arterial myocytes is unclear. P2Y~11~ receptors were first cloned from human tissue and subsequently identified in other species ([@bib42]; [@bib80]). Although the P2Y~11~ gene has not been found at the expected position in the mouse genome, recent rodent annotations related to this gene (e.g. XM_008766009.2 and XM_0130655917.2), as well as studies defining a functional role based on pharmacological data obtained from rat and mouse tissue hinted at the presence of at least a P2Y~11~-like receptor in mice ([@bib42]). We, therefore, undertook a comprehensive approach to investigate whether upstream engagement of this G~s~-coupled P2Y receptor is implicated in PKA activation leading to increased Ser^1928^ phosphorylation of vascular Ca~V~1.2 that results in potentiation of LTCC activity during diabetic hyperglycemia. Accordingly, Western blot analysis, immunofluorescence confocal microscopy, Ground State Depletion (GSD) super-resolution nanoscopy, FRET-based cAMP imaging and voltage-clamp electrophysiology confirmed functional expression of P2Y~11~ in human arterial myocytes. We found that elevated glucose stimulates cAMP synthesis with the same magnitude as that observed upon application of the selective P2Y~11~ agonist NF546 or when both stimuli were given simultaneously, thus suggesting that glucose and NF546 signaling proceed through the same pathway. Nanometer proximity was observed between P2Y~11~ and PKA and P2Y~11~ and Ca~V~1.2 at the sarcolemma of arterial myocytes, which facilitates a structural arrangement that may be essential for glucose effects on LTCC activity. Indeed, the NF546/glucose-induced cAMP signal resulted in enhanced Ser^1928^ phosphorylation and LTCC activity in human arterial myocytes, and these changes were prevented by the selective P2Y~11~ inhibitor NF340. Intriguingly, comparable functional data were observed in mouse arterial myocytes, suggesting that a P2Y~11~-like receptor could be mediating the glucose response in these cells that results in vasoconstriction ([@bib42]). Thus, our data in human and murine tissue indicate a key role for a G~s~-coupled P2Y receptor, which fits the distribution, pharmacological, and signaling profile of a P2Y~11~ or P2Y~11~-like receptor, respectively, as an upstream player in the regulation of LTCCs and vascular reactivity during diabetic hyperglycemia. These findings may have important clinical and therapeutic implications as they may point to P2Y~11~ as a potential target for treating diabetic vascular complications.

Results {#s2}
=======

Glucose-induced extracellular nucleotide release mediates Ser^1928^ phosphorylation, increased LTCC activity and vasoconstriction {#s2-1}
---------------------------------------------------------------------------------------------------------------------------------

In our first series of experiments, we pressurized (60 mmHg) mouse cerebral arteries to develop stable and spontaneous tone ([Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). When increasing extracellular glucose from 10 mM to 20 mM D-glucose, there was a significant constriction ([Figure 1A](#fig1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}), which is consistent with previous reports by our group and others ([@bib40]; [@bib68]). These extracellular D-glucose concentrations are used because they are within the range of observed nonfasting glucose levels in nondiabetic and diabetic mouse models ([@bib46]; [@bib53]; [@bib60]; [@bib61]; [@bib67]; [@bib68]). Considering that elevating glucose in the external milieu may trigger autocrine release of nucleotides ([@bib17]; [@bib37]; [@bib64]; [@bib69]), we investigated whether hydrolysis of extracellular nucleotides would ablate glucose-mediated vasoconstriction. For these experiments, pressurized arteries (60 mmHg) were pre-treated with the ectonucleotidase apyrase (0.32 U/mL) in a 10 mM D-glucose solution for 10 min. Apyrase-treated arteries failed to constrict to 20 mM D-glucose ([Figure 1A](#fig1){ref-type="fig"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Vasoconstriction in response to 60 mM potassium (K^+^) in which the membrane potential closely follows the equilibrium potential for K^+^ (\~−20 mV) ([@bib45]), was similar in control and apyrase-treated arteries ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). These results suggest that differences in glucose-induced vasoconstriction were not due to an inability of apyrase-treated arteries to respond to 20 mM D-glucose. Furthermore, the glucose-induced constriction was not attributed to changes in osmolarity as treatment with equimolar concentrations of the nonpermeable mannitol (20 mM = 10 mM D-glucose +10 mM mannitol) had no effect on vascular reactivity ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}).

![Extracellular nucleotides promote vasoconstriction, Ca~V~1.2 activity and Ser^1928^ phosphorylation in response to 20 mM D-glucose in murine arterial myocytes.\
(**A**) Representative diameter recordings and summary arterial tone data from pressurized (60 mmHg) wt mouse cerebral arteries before and after application of 20 mM D-glucose in the absence (n = 6 arteries from six mice) and presence (n = 6 arteries from six mice) of apyrase (apy; 0.32 U/ml; \*p\<0.05, Wilcoxon matched pairs test; [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). (**B**) Characteristic I~Ba~ recordings from the same cell and summary I~Ba~ data from wt mouse cerebral arterial myocytes evoked by step depolarizations from −70 to +10 mV before and after application of 20 mM D-glucose in the absence (n = 11 cells from five mice) and presence of apyrase (n = 9 cells from five mice) (\*p\<0.05, paired *t* test; [Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}). (**C**) Representative immunoblot detection of phosphorylated Ser^1928^ (pSer^1928^) and total Ca~V~1.2 from wt mouse cerebral and mesenteric arteries after 10 min incubation with 10 mM or 20 mM D-glucose in the absence and presence of apyrase (n = 10 arterial lysates per condition), and quantification of pSer^1928^ (AU = arbitrary units) (\*p\<0.05, Kruskal-Wallis with Dunn's multiple comparisons; [Figure 1---source data 3](#fig1sdata3){ref-type="supplementary-material"}).\
10.7554/eLife.42214.010Figure 1---source data 1.Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in [Figure 1A](#fig1){ref-type="fig"} and corresponding raw diameters.\
10.7554/eLife.42214.011Figure 1---source data 2.Excel spreadsheet containing the individual numeric values of current density analyzed in [Figure 1B](#fig1){ref-type="fig"}.\
10.7554/eLife.42214.012Figure 1---source data 3.Excel spreadsheet containing the individual numeric values of pSer^1928^/Ca~V~1.2 relative density analyzed in [Figure 1C](#fig1){ref-type="fig"}.](elife-42214-fig1){#fig1}

LTCC activity is critical for vascular reactivity ([@bib45]), and its function is enhanced in response to acute increases in glucose and in diabetes due to increased Ser^1928^ phosphorylation in the Ca~V~1.2 carboxy terminal ([@bib56]; [@bib60]; [@bib68]). We, thus, examined whether nucleotide degradation with apyrase prevents glucose-mediated increases in LTCC activity and Ser^1928^ phosphorylation. To assess this, we used ﻿patch-clamp electrophysiology in the whole-cell perforated configuration with barium (Ba^2+^) as the charge carrier, before and after application of nifedipine to determine the nifedipine-sensitive Ba^2+^ current (I~Ba~) associated with LTCC activity in control and apyrase-treated cerebral arterial myocytes. We found that 20 mM D-glucose significantly enhanced I~Ba~ in wild type (wt) control arterial myocytes, but not in apyrase-treated cells ([Figure 1B](#fig1){ref-type="fig"}). The glucose effect on LTCC activity was not due to changes in osmolarity as 20 mM mannitol had no impact on I~Ba~ ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}).

We next performed Western blot analysis with a specific phospho-antibody against Ser^1928^ at Ca~V~1.2 and a FP1 antibody for total Ca~V~1.2 detection that have been extensively validated by our group ([@bib12]; [@bib18]; [@bib36]; [@bib68]; [@bib70]). Indeed, we have previously shown that the immunoreactivity at 250 kDa of Ca~V~1.2 with the phospho-specific antibody for Ser^1928^ (but not a phospho-specific antibody for Ser^1700^) and FP1 are completely eliminated in tissue from S1928A knockin mice ([@bib70]) and conditional Ca~V~1.2 knockout mice ([@bib12]), respectively. Data revealed increased phosphorylation of this residue in response to 20 mM D-glucose in control arterial lysates ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). However, this response was completely absent in arterial lysates exposed to 20 mM mannitol, thus ruling out any osmolarity effects ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). Moreover, glucose-induced Ser^1928^ phosphorylation was hindered in lysates from apyrase-treated arteries ([Figure 1C](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}). These results suggest that elevated glucose increases Ser^1928^ phosphorylation to potentiate LTCC activity through an autocrine mechanism involving secreted nucleotides.

To further test this possibility, LTCC activity was recorded in response to elevated glucose during continuous perfusion or static bath conditions (as above). The rationale for these experiments was to determine whether the wash out of nucleotides with flow can impact the glucose-induced potentiation of LTCCs. We found statistically similar I~Ba~ in cells exposed to 10 mM and 20 mM D-glucose under continuous bath perfusion ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Conversely, I~Ba~ was significantly elevated in arterial myocytes exposed to 20 mM D-glucose when the bath perfusion was stopped (e.g. static bath conditions). These results suggest that secreted nucleotides could diffuse away under continuous flow, whereas under static bath conditions, they could accumulate in or around the area of release at the surface membrane of arterial myocytes to induce the optimal activation of the signaling pathway underlying increased LTCC activity in response to elevations in extracellular glucose.

P2Y~11~ receptors are in close proximity to Ca~V~1.2 and PKA~cat~ in arterial myocytes {#s2-2}
--------------------------------------------------------------------------------------

Extracellular nucleotides are well-known activators of G-coupled P2Y receptors ([@bib80]). P2Y~11~ is a G~s~-coupled P2Y receptor that could activate PKA ([@bib14]; [@bib42]; [@bib75]; [@bib80]), and this could lead to enhanced Ser^1928^ phosphorylation, LTCC activity, and vasoconstriction during diabetic hyperglycemia. Using Western blot analysis, we first validated the P2Y~11~ antibody in tsA-201 cells, which endogenously express P2Y~11~ ([@bib26]), by over-expressing human GFP-tagged P2Y~11~ and by knocking down the endogenous and over-expressed receptor with specific P2Y~11~ antisense oligodeoxynucleotides (ODNs) ([Figure 2A and B](#fig2){ref-type="fig"}). We subsequently detected an immunoreactive band of the expected molecular weight for P2Y~11~ (\~40 kDa) in lysates from freshly dissected human adipose arteries ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). This band seems specific for P2Y~11 ~since treatment of human arteries with specific human P2Y~11~ antisense ODNs knocked down \~50% of the basal P2Y~11~ protein abundance ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Confocal imaging and line profile analysis of P2Y~11~-associated fluorescence and the plasma membrane marker wheat germ agglutinin (WGA) suggest a prominent distribution of the receptor on the surface membrane of freshly dissociated human arterial myocytes ([Figure 2D and E](#fig2){ref-type="fig"}). This was not observed when the antibody for P2Y~11~ was omitted from the preparation ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). These results suggest expression of P2Y~11~ in human arterial myocytes. We observed comparable results in mouse arterial lysates and arterial myocytes, including detection and knock down with P2Y~11~ ODNs of an immunoreactive band of the expected molecular weight for P2Y~11~ ([Figure 2C](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1A, B and D](#fig2s1){ref-type="fig"}). A band of \~110--120 kDa was observed in mouse arterial lysates, perhaps reflecting the formation of heterodimers between the P2Y~11~ receptor itself or other purinergic/G protein-coupled receptors, as previously reported ([@bib7]; [@bib6]; [@bib27]; [@bib65]). We also found expected distribution of P2Y~11~-like-associated fluorescence at the surface membrane of mouse arterial myocytes ([Figure 2D and E](#fig2){ref-type="fig"}), which was not observed when the primary antibody was omitted or boiled ([Figure 2---figure supplement 1C and E](#fig2s1){ref-type="fig"}).

![P2Y~11~ protein and distribution in arterial myocytes.\
(**A**) Representative blot of immunoreactive bands of expected molecular weight for endogenous P2Y~11~ (\~40 kDa), overexpressed P2Y~11~-GFP (\~70 kDa), and β-actin (\~43 kDa) in untransfected, vehicle-treated (empty transfection) and P2Y~11~-GFP transfected tsA-201 cells (n = 3 lysates per condition). Note that tsA-201 cells endogenously express P2Y~11~ ([@bib26]). (**B**) Representative blot of immunoreactive bands of expected molecular weight for endogenous P2Y~11~ (\~40 kDa), overexpressed P2Y~11~-GFP (\~70 kDa), and β-actin (\~43 kDa) in tsA-cells transfected with P2Y~11~-GFP as well as corresponding P2Y~11~ sense (SNS) or antisense (ANS) ODNs (64% reduction in endogenous P2Y~11~ expression in cells treated with ANS; 62% reduction in P2Y~11~-GFP expression in P2Y~11~-GFP-transfected cells treated with ANS; n = 3 lysates per condition; [Figure 2---source data 1](#fig2sdata1){ref-type="supplementary-material"}). (**C**) Representative immunoblot detection of P2Y~11~ (\~40 kDa) in lysates from human and wt mouse arteries (n = 3 arterial lysates per sample). (**D**) Representative confocal images of P2Y~11~-associated fluorescence (green), wheat germ agglutinin (WGA, red) and merged channels in human (n = 11 cells from three humans) and wt mouse (n = 14 cells from three mice) arterial myocytes. (**E**) Line profile of the P2Y~11~- and WGA-associated fluorescence from the area highlighted by the dotted lines in the representative human and mouse arterial myocytes in D.\
10.7554/eLife.42214.016Figure 2---source data 1.Excel spreadsheet containing the individual numeric values of P2Y~11~/ β-actin relative density corresponding to values reported in legend of [Figure 2B](#fig2){ref-type="fig"}.](elife-42214-fig2){#fig2}

If P2Y~11~ is involved in PKA-mediated activation of LTCCs in response to elevated glucose, we hypothesized that a subpopulation of these receptors should be localized in close proximity to Ca~V~1.2 and PKA~cat~. To test this possibility, we examined the spatial relationship of P2Y~11~ with Ca~V~1.2 and PKA~cat~ in freshly dissociated human arterial myocytes using GSD super-resolution nanoscopy in the Total Internal Reflection Fluorescence (TIRF) configuration. This approach achieves a lateral resolution of \~20 nm with selective illumination of the (sub)sarcolemmal region. Note that the FP1 antibody against Ca~V~1.2 has been extensively validated by our group ([@bib12]; [@bib36]; [@bib68]; [@bib70]). The PKA~cat~ antibody was validated in arterial myocytes by pre-absorption with a blocking peptide ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). The GSD super-resolution localization maps ([Figure 3A and B](#fig3){ref-type="fig"}, *bottom panels*) for P2Y~11~, Ca~V~1.2, and PKA~cat~ obtained from conventional TIRF images ([Figure 3A and B](#fig3){ref-type="fig"}, *top panels*) showed that these proteins form clusters of various sizes ([Figure 3C](#fig3){ref-type="fig"}) and density ([Figure 3D](#fig3){ref-type="fig"}) at the sarcolemma of human arterial myocytes. Whereas clusters were broadly expressed throughout the sarcolemma, merged spatial maps of P2Y~11~ with Ca~V~1.2 or PKA~cat~ suggested a close association between a subset of these proteins ([Figure 3E and F](#fig3){ref-type="fig"}). Indeed, histograms of the P2Y~11~-to-nearest Ca~V~1.2 or PKA~cat~ distances revealed that the closest centroids for P2Y~11~-Ca~V~1.2 and P2Y~11~- PKA~cat~ were at 59 nm and 58 nm, respectively ([Figure 3G and H](#fig3){ref-type="fig"}). Similar results were observed using freshly dissociated mouse cerebral arterial myocytes ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). Clusters of P2Y~11~, Ca~V~1.2, or PKA~cat~ were never observed when primary antibodies were omitted from the human or mouse preparation ([Figure 3---figure supplement 3A and B](#fig3s3){ref-type="fig"}). To determine whether the interaction between a subpopulation of P2Y~11~ with a pool of Ca~V~1.2 and PKA in arterial myocytes is the result of specific organization between two proteins, we compared the percentage of P2Y~11~ and Ca~V~1.2/PKA~cat~ overlap between experimental super-resolution localization maps and images containing randomized distribution of P2Y~11~, Ca~V~1.2 and PKA~cat~. Randomized images for P2Y~11~-Ca~V~1.2 and P2Y~11~-PKA~cat~ were generated based on data derived from the experimental super-resolution localization maps for these pairs of proteins using the Coste's randomization algorithm included in the JACoP plug-in in ImageJ ([@bib9]). Our analysis found that the percentage of overlap between P2Y~11~-Ca~V~1.2 and P2Y~11~-PKA~cat~ obtained from the experimental localization maps was significantly higher than that observed for a simulated random distribution between P2Y~11~-Ca~V~1.2 and P2Y~11~-PKA~cat~ ([Figure 3I](#fig3){ref-type="fig"} and [Figure 3---figure supplement 3C](#fig3s3){ref-type="fig"}). These results suggest an intimate association between subpopulations of P2Y~11~-Ca~V~1.2 and P2Y~11~-PKA~cat~.

![Nanometer organization of P2Y~11~ with Ca~V~1.2 and PKA~cat~ in human arterial myocytes.\
Representative conventional TIRF images (top) and corresponding GSD reconstruction maps (bottom) from human arterial myocytes labeled for (**A**) P2Y~11~ and Ca~V~1.2 and (**B**) P2Y~11~ and PKA~cat~. Lower panels display enhanced magnifications of areas shown in yellow boxes (scale bar, 400 nm). (**C**) Histograms of the area of P2Y~11~, Ca~V~1.2 and PKA~cat~ clusters in isolated human arterial myocytes (1621 ± 29, 1209 ± 16 and 1322 ± 20 nm^2^, respectively; [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). (**D**) Bar plot of cluster density for P2Y~11~, Ca~V~1.2 and PKA~cat~ (38 ± 2, 29 ± 4, and 25 ± 3 clusters/µm^2^, respectively; [Figure 3---source data 2](#fig3sdata2){ref-type="supplementary-material"}). Enlarged merged image (*left*) and associated *x-y* fluorescence intensity profile (*right*) from area highlighted by the dotted lines of sites of close proximity between (**E**) P2Y~11~ (red) and Ca~V~1.2 (green) and (**F**) P2Y~11~ (red) and PKA~cat~ (green) (scale bar, 200 nm). Histograms of the lowest intermolecular distance to P2Y~11~ centroids for (**G**) Ca~V~1.2 (n = 19,611 particles from 6 cells; [Figure 3---source data 3](#fig3sdata3){ref-type="supplementary-material"}) and (**H**) PKA~cat~ (n = 22,425 particles from 6 cells; [Figure 3---source data 4](#fig3sdata4){ref-type="supplementary-material"}) fluorescence particles. Data were fit with a sum of two Gaussian functions with depicted R^2^ and centroids. (**I**) Bar plot of % overlap of P2Y~11~ with Ca~V~1.2 or PKA~cat~ for experimental (Ca~V~1.2: n = 36 segments from 12 cells; PKA~cat~: n = 22 segments from 11 cells) and randomized simulations images (Ca~V~1.2: n = 6 segments from 6 cells; PKA~cat~: n = 6 segments from 6 cells) (\*p\<0.05, unpaired *t* test with Welch's correction; [Figure 3---source data 5](#fig3sdata5){ref-type="supplementary-material"}).\
10.7554/eLife.42214.025Figure 3---source data 1.Excel spreadsheet containing the individual numeric values of frequency distribution histograms for cluster area in [Figure 3C](#fig3){ref-type="fig"}.\
10.7554/eLife.42214.026Figure 3---source data 2.Excel spreadsheet containing the individual numeric values for cluster density in [Figure 3D](#fig3){ref-type="fig"}.\
10.7554/eLife.42214.027Figure 3---source data 3.Excel spreadsheet containing the individual numeric values of frequency distribution histograms for intermolecular distance in [Figure 3G](#fig3){ref-type="fig"}.\
10.7554/eLife.42214.028Figure 3---source data 4.Excel spreadsheet containing the individual numeric values of frequency distribution histograms for intermolecular distance in [Figure 3H](#fig3){ref-type="fig"}.\
10.7554/eLife.42214.029Figure 3---source data 5.Excel spreadsheet containing the individual numeric values for % of P2Y~11~ overlap in [Figure 3I](#fig3){ref-type="fig"}.](elife-42214-fig3){#fig3}

We used the proximity ligation assay (PLA) as an additional analytical tool to examine the association between P2Y~11~ and Ca~V~1.2 or PKA~cat~. PLA fluorescence puncta are only observed if proteins of interest are 40 nm or less apart ([@bib32]). We have extensively validated this approach in previous studies ([@bib62]; [@bib68]). Whereas PLA signals were absent when at least one primary antibody was omitted ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), robust fluorescent puncta were detected in human ([Figure 4A and B](#fig4){ref-type="fig"}) and mouse ([Figure 4C and D](#fig4){ref-type="fig"}) arterial myocytes co-labeled for P2Y~11~ and Ca~V~1.2 or P2Y~11~ and PKA~cat~. Altogether, these results suggest that human P2Y~11~ or mouse P2Y~11~-like receptors are located on the surface membrane of arterial myocytes within nanometer proximity (\~≤40 nm) of a subpopulation of Ca~V~1.2 and PKA~cat~.

![P2Y~11~ associates with Ca~V~1.2 and PKA~cat~ in human and murine arterial myocytes.\
(**A**) Exemplary fluorescence PLA (red)/DAPI (blue) and differential interference contrast (right) images of human arterial myocytes labeled for P2Y~11~ + Ca~V~1.2 and P2Y~11~ + PKA~cat~. (**B**) Quantification of PLA fluorescent puncta per cell area (puncta/µm^2^) for human arterial myocytes labeled for P2Y~11~ (n = 26 cells from three human samples), Ca~V~1.2 (n = 20 cells from three humans), PKA~cat~ (n = 17 cells from three humans), P2Y~11~ + Ca~V~1.2 (n = 23 cells from three humans), and P2Y~11~ + PKA~cat~ (n = 20 cells from three humans) (\*p\<0.05, Kruskal-Wallis with Dunn's multiple comparisons; [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). (**C**) Representative fluorescence PLA (red)/DAPI (blue) and differential interference contrast (right) images of mouse arterial myocytes labeled for P2Y~11~ + Ca~V~1.2 and P2Y~11~ + PKA~cat~. (**D**) Quantification of PLA fluorescent puncta per µm^2^ cell area for mouse arterial myocytes labeled for P2Y~11~ (n = 44 cells from six mice), Ca~V~1.2 (n = 15 cells from six mice), PKA~cat~ (n = 19 cells from six mice), P2Y~11~ + Ca~V~1.2 (n = 25 cells from six mice), and P2Y~11~ + PKA~cat~ (n = 29 cells from six mice) (\*p\<0.05, Kruskal-Wallis with Dunn's multiple comparisons; [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}).\
10.7554/eLife.42214.032Figure 4---source data 1.Excel spreadsheet containing the individual numeric values of puncta/µm^2^ graphs in [Figure 4B](#fig4){ref-type="fig"}.\
10.7554/eLife.42214.033Figure 4---source data 2.Excel spreadsheet containing the individual numeric values of puncta/µm^2^ graphs in [Figure 4D](#fig4){ref-type="fig"}.](elife-42214-fig4){#fig4}

Increased sarcolemmal cAMP synthesis in arterial myocytes in response to a P2Y~11~ agonist recapitulates glucose effects {#s2-3}
------------------------------------------------------------------------------------------------------------------------

P2Y~11~ can stimulate adenylyl cyclase (AC) activity to produce cAMP ([@bib14]; [@bib42]; [@bib75]; [@bib80]). Thus, we first used a membrane-targeted Epac1-camps-based FRET sensor (ICUE3-PM) ([@bib2]; [@bib49]) expressed in tsA-201 cells to validate the P2Y~11~ pharmacology ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}) ([@bib26]). As expected, the highly selective P2Y~11~ agonist NF546 (500 nM) ([@bib52]) increased cAMP synthesis in these cells. This NF546-induced cAMP response remained intact in cells pretreated with either selective P2Y~1~ (10 µM MRS2179) or P2Y~6~ (100 nM MRS2578) inhibitors but was prevented in cells exposed to the selective P2Y~11~ inhibitor NF340 (10 µM; 500-fold more selective for P2Y~11~ than other P2Y receptors) ([@bib52]).

We recapitulated the NF546-induced cAMP response and its ablation by pretreatment with NF340 in primary, unpassaged human arterial myocytes expressing the ICUE3-PM sensor ([Figure 5A and B](#fig5){ref-type="fig"}). Increasing D-glucose concentration from 5 mM to 15 mM, which are glucose concentrations comparable to those observed in nondiabetic and diabetic patients respectively, induced a small yet significant increase in cAMP synthesis in human cells ([Figure 5A and B](#fig5){ref-type="fig"}). The glucose effects are not due to osmotic changes as equimolar concentrations of the non-permeable mannitol did not induce any cAMP synthesis ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). As expected, the synthesis of cAMP was further amplified by the broad AC activator forskolin (1 μM) ([Figure 5A](#fig5){ref-type="fig"}) even in the presence of 20 mM mannitol ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Simultaneous application of 15 mM D-glucose +NF546 resulted in cAMP synthesis of a similar magnitude to that induced by independent treatments ([Figure 5A and B](#fig5){ref-type="fig"}). This suggests that the effects of elevated glucose and the NF546 compound may be acting through a similar pathway that requires activation of P2Y~11~. Consistent with this notion, application of NF546 by itself or 15 mM D-glucose +NF546 failed to induce cAMP synthesis in cells pretreated with NF340 ([Figure 5A and B](#fig5){ref-type="fig"}). Yet forskolin, which bypasses P2Y~11~, was still able to stimulate global cAMP production. Similar results were observed in murine arterial myocytes expressing the ICUE3-PM sensor ([Figure 5C and D](#fig5){ref-type="fig"} and [Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Intriguingly, cAMP synthesis in response to elevated glucose and the P2Y~11~ agonist NF546 was significantly larger in human myocytes compared to mouse cells (glucose: 0.077 ± 0.003 in human vs 0.045 ± 0.002 in mouse; NF546: 0.083 ± 0.005 in human vs 0.045 ± 0.004 in mouse; p\<0.05). The reasons for this are currently unclear but may include intrinsic differences associated with species (human vs mouse), blood vessels (human adipose arteries vs mouse aortae) and expression patterns of the biosensor in human vs mouse cells ([@bib74]), as well as variations in protein expression and receptor/enzyme activity (e.g. P2Y~11~, AC and PDE expression/activity) in human vs mouse arterial myocytes. Whether either or all of these factors contribute to distinctive cAMP responses in human vs mouse arterial myocytes as well as their physiological implications remain to be determined. Nevertheless, our findings suggest a role for human P2Y~11~ and mouse P2Y~11~-like receptors in glucose-induced cAMP synthesis.

![Glucose and the P2Y~11~ agonist NF546 increase sarcolemmal cAMP synthesis in arterial myocytes, and these effects are prevented by the P2Y~11~ antagonist NF340.\
(**A**) Time course of YFP/CFP (donor/acceptor) FRET ratios (normalized to resting levels before treatment) in human arterial myocytes expressing the ICUE3-PM biosensor in response to 15 mM D-glucose (black; n = 19 cells from two humans), 500 nM NF546 (green; n = 18 cells from two humans) and 15 mM D-glucose +500 nM NF546 (red; n = 14 cells from two humans) before and after application of broad adenylyl cyclase agonist forskolin (1 µM). In a set of experiments, cells were first pre-treated with the P2Y~11~ antagonist NF340 (10 µM) for at least 15--20 min before treatment with 500 nM NF546 (orange; n = 15 cells from two humans) and 15 mM D-glucose +500 nM NF546 (blue; n = 13 cells from two humans). Horizontal bars indicate treatment. Increases in cAMP production are represented by decreases in YFP/CFP ratio due to binding of cAMP to the biosensor. (**B**) Bar plot of maximum FRET responses (YFP/CFP) for human arterial myocytes in response to the indicated treatment (\*p\<0.05, Kruskal-Wallis with Dunn's multiple comparisons; [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}. Statistical differences were compared between 15 mM D-glucose vs NF546, 15 mM D-glucose vs 15 mM D-glucose +NF546, 15 mM D-glucose vs NF546 +NF340, 15 mM D-glucose vs 15 mM D-glucose +NF546+NF340, NF546 vs NF546 +NF340, NF546 vs 15 mM D-glucose +NF546, NF546 vs 15 mM D-glucose +NF546+NF340, 15 mM D-glucose +NF546 vs 15 mM D-glucose +NF546+NF340). (**C**) Time course of YFP/CFP (donor/acceptor) FRET ratios (normalized to resting levels before treatment) in mouse arterial myocytes expressing the ICUE3-PM biosensor in response to 20 mM D-glucose (black; n = 83 cells from three mice), 500 nM NF546 (green; n = 13 cells from three mice) and 20 mM D-glucose +500 nM NF546 (red; n = 13 cells from three mice). Horizontal bars indicate treatment. In a set of experiments, cells were first pre-treated with the P2Y~11~ antagonist NF340 (10 µM) for at least 15--20 min before treatment with 500 nM NF546 (orange; n = 17 cells from three mice) and 20 mM D-glucose +500 nM NF546 (blue; n = 18 cells from three mice). Increases in cAMP production are represented by decreases in YFP/CFP ratio due to binding of cAMP to the biosensor. (**D**) Bar plot of maximum FRET responses (YFP/CFP) for mouse arterial myocytes in response to the indicated treatment (\*p\<0.05, Kruskal-Wallis with Dunn's multiple comparisons; [Figure 5---source data 2](#fig5sdata2){ref-type="supplementary-material"}. Statistical differences were compared between all datasets).\
10.7554/eLife.42214.039Figure 5---source data 1.Excel spreadsheet containing the individual numeric values for maximum FRET responses in [Figure 5B](#fig5){ref-type="fig"}.\
10.7554/eLife.42214.040Figure 5---source data 2.Excel spreadsheet containing the individual numeric values for maximum FRET responses in [Figure 5D](#fig5){ref-type="fig"}.](elife-42214-fig5){#fig5}

The P2Y~11~ inhibitor NF340 prevents glucose-induced Ser^1928^ phosphorylation, LTCC activity and vasoconstriction {#s2-4}
------------------------------------------------------------------------------------------------------------------

In our next series of experiments, we confirmed the glucose-induced increase in I~Ba~ detected in mouse arterial myocytes ([Figure 1B](#fig1){ref-type="fig"}) using freshly dissociated human arterial myocytes in which external glucose was elevated from 5 mM to 15 mM ([Figure 6A and B](#fig6){ref-type="fig"}). These results indicate that elevations in extracellular glucose also stimulate LTCC activity in human arterial myocytes ([@bib68]). The increase in I~Ba~ evoked by 15 mM D-glucose was prevented in human cells pretreated with NF340 ([Figure 6A and B](#fig6){ref-type="fig"}). Glucose-induced potentiation of I~Ba~ was also prevented in mouse arterial myocytes pretreated with NF340 ([Figure 6C and D](#fig6){ref-type="fig"}). However, inhibition of P2Y~6~ receptors with MRS2578, which has been implicated in myogenic tone regulation and glucose-induced NFAT activation in arterial myocytes ([@bib10]; [@bib64]), failed to stop the increase in I~Ba~ in response to 20 mM D-glucose ([Figure 6C and D](#fig6){ref-type="fig"}). Note that basal I~Ba~ were similar in cells exposed to 10 mM D-glucose and 10 mM D-glucose +MRS2578, suggesting that inhibition of P2Y~6~ did not alter basal LTCC activity ([Figure 6C and D](#fig6){ref-type="fig"}). Altogether, these results suggest that P2Y~6~ receptors are not involved in glucose-induced potentiation of LTCC activity, and that these glucose effects are prevented with a P2Y~11~ inhibitor.

![The P2Y~11~ inhibitor NF340 prevents glucose-induced elevations in Ser^1928^ phosphorylation, LTCC activity, and vasoconstriction in human and murine arterial myocytes.\
(**A**) Representative I~Ba~ recordings from the same cell and (**B**) summary current density data obtained from freshly dissociated human arterial myocytes before and after increasing extracellular D-glucose from 5 mM to 15 mM in the absence (n = 12 cells from six humans) and presence (n = 10 cells from five humans) of NF340 (10 µM) (\*p\<0.05, paired *t* test; [Figure 6---source data 1](#fig6sdata1){ref-type="supplementary-material"}). (**C**) Exemplary I~Ba~ traces from the same cell and (**D**) amalgamated current density data recorded from mouse cerebral arterial myocytes treated with 10 µM NF340 (n = 8 cells from three mice) or 100 nM MRS2578 (n = 7 cells from five mice) before and after increasing extracellular D-glucose from 10 mM to 20 mM (\*p\<0.05, Kruskal-Wallis with Dunn's multiple comparisons; [Figure 6---source data 2](#fig6sdata2){ref-type="supplementary-material"}). Representative immunoreactive bands for phosphorylated Ser^1928^ (pSer^1928^) and total Ca~V~1.2 and densitometry for pSer^1928^/Ca~V~1.2 ratio in lysates from (**E**) human arteries exposed to 5 mM and 15 mM D-glucose in the absence and presence of 10 µM NF340 (n = 6 arterial lysates per condition; \*p\<0.05, Kruskal-Wallis with Dunn's multiple comparisons; [Figure 6---source data 3](#fig6sdata3){ref-type="supplementary-material"}) and (**F**) mouse cerebral and mesenteric arteries exposed to 10 mM or 20 mM D-glucose in the presence of 10 µM NF340 or 100 nM MRS2578 (n = 4 arterial lysates per condition; \*p\<0.05 Kruskal-Wallis with Dunn's multiple comparisons; [Figure 6---source data 4](#fig6sdata4){ref-type="supplementary-material"}). Representative diameter recordings and summary data from pressurized (60 mmHg) mouse cerebral arteries exposed to (**G--H**) 10 µM NF340 (n = 4 arteries from four mice; Friedman with Dunn's multiple comparisons; [Figure 6---source data 5](#fig6sdata5){ref-type="supplementary-material"}) or (**I--J**) 100 nM MRS2578 (n = 7 arteries from seven mice; \*p\<0.05, Wilcoxon matched pair test; [Figure 6---source data 6](#fig6sdata6){ref-type="supplementary-material"}) before and after application of 20 mM D-glucose.\
10.7554/eLife.42214.046Figure 6---source data 1.Excel spreadsheet containing the individual numeric values of current density analyzed in [Figure 6B](#fig6){ref-type="fig"}.\
10.7554/eLife.42214.047Figure 6---source data 2.Excel spreadsheet containing the individual numeric values of current density analyzed in [Figure 6D](#fig6){ref-type="fig"}.\
10.7554/eLife.42214.048Figure 6---source data 3.Excel spreadsheet containing the individual numeric values of pSer^1928^/Ca~V~1.2 relative density analyzed in [Figure 6E](#fig6){ref-type="fig"}.\
10.7554/eLife.42214.049Figure 6---source data 4.Excel spreadsheet containing the individual numeric values of pSer^1928^/Ca~V~1.2 relative density analyzed in [Figure 6F](#fig6){ref-type="fig"}.\
10.7554/eLife.42214.050Figure 6---source data 5.Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in [Figure 6H](#fig6){ref-type="fig"} and corresponding raw diameters.\
10.7554/eLife.42214.051Figure 6---source data 6.Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in [Figure 6J](#fig6){ref-type="fig"} and corresponding raw diameters.](elife-42214-fig6){#fig6}

Since the P2Y~11~ inhibitor hindered the glucose effects on LTCC activity, we also explored whether the NF340 compound interfered with the Ser^1928^ phosphorylation state of the channel and vascular reactivity in response to hyperglycemia. As observed in mouse arteries ([Figure 1C](#fig1){ref-type="fig"}), we found that elevating extracellular glucose significantly increased Ser^1928^ phosphorylation in human arterial lysates ([Figure 6E](#fig6){ref-type="fig"}; [Figure 6---figure supplement 1A](#fig6s1){ref-type="fig"}). Yet, this glucose-mediated increase in Ser^1928^ phosphorylation was prevented if arterial lysates were pretreated with NF340, whereas phosphorylation still occurred if arterial lysates were pretreated with the P2Y~6~ inhibitor MRS2578 ([Figure 6E and F](#fig6){ref-type="fig"}, and [Figure 6---figure supplement 1A and B](#fig6s1){ref-type="fig"}). Furthermore, vasoconstriction in response to elevated glucose was blocked in pressurized (60 mmHg) mouse cerebral arteries exposed to NF340 ([Figure 6G and H](#fig6){ref-type="fig"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}) but not to MRS2578 ([Figure 6I and J](#fig6){ref-type="fig"} and [Supplementary file 2](#supp2){ref-type="supplementary-material"}). Note that while arterial tone was similar in control and NF340-treated arteries, it was reduced in arteries exposed to MRS2578 ([Figure 6I and J](#fig6){ref-type="fig"}), which is in line with recent data showing that P2Y~6~ is a sensor of pressure-induced constriction ([@bib10]). Vasoconstriction in response to 60 mM K^+^ was similar in control and NF340 as well as MRS2578-treated arteries ([Figure 6---figure supplement 1C](#fig6s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). We also evaluated a potential role for P2Y~1~ receptors in stimulating PKA-mediated vasoconstriction as these receptors have been suggested to crosstalk with P2Y~11~ to regulate their function in HEK cells and neurons ([@bib22]; [@bib43]). Data revealed that the glucose-induced vasoconstriction was not altered by adding the selective P2Y~1~ inhibitor MRS2179 (10 μM) either before or after 20 mM D-glucose stimulation ([Figure 6---figure supplement 1D and E](#fig6s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). These results suggest that the P2Y~1~ receptor is not involved in glucose-mediated vasoconstriction. Together, these data demonstrate the effectiveness of a P2Y~11~ inhibitor in blocking the remodeling of Ser^1928^ phosphorylation and LTCC activity that mediates vasoconstriction in response to elevated glucose.

The P2Y~11~ agonist NF546 stimulates Ser^1928^ phosphorylation, PKA-dependent LTCC activity and vasoconstriction {#s2-5}
----------------------------------------------------------------------------------------------------------------

We next investigated whether a selective P2Y~11~ agonist could recapitulate the glucose-mediated Ser^1928^ phosphorylation and PKA-dependent LTCC activity. Using freshly dissociated human arterial myocytes, we found that I~Ba~ was significantly increased by application of NF546 ([Figure 7A](#fig7){ref-type="fig"}). This P2Y~11~ agonist also increased I~Ba~ at multiple membrane potentials in mouse arterial myocytes with no change in the current-voltage (I-V) relationship (V~max~ = 14.9 ± 2.0 mV for 10 mM D-glucose and V~max~ = 10.9 ± 1.1 mV for NF546; p=0.1085, extra sum-of-squares *F* test) ([Figure 7B](#fig7){ref-type="fig"}). The NF546-mediated increase in I~Ba~ was similar in magnitude to that induced by elevated glucose ([Figure 7---figure supplement 1A](#fig7s1){ref-type="fig"}). Similar I~Ba~ potentiation was also observed after application of the non-hydrolyzed ATP analog and potent P2Y~11~ agonist ATPγS (1 μM; [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}) ([@bib80]). Note that ATPγS stimulates P2Y~11~ activity with EC~50~ that ranges from 31 nM to 23 μM, depending on readout, cell type and species used, but it is still a more potent activator than ATP itself ([@bib15]; [@bib34]; [@bib42]; [@bib52]; [@bib72]; [@bib75]; [@bib80]). We further correlated the potentiation in I~Ba~ by NF546 to an elevation of Ser^1928^ phosphorylation in freshly dissected human and mouse arterial lysates ([Figure 7C](#fig7){ref-type="fig"} and [Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}). Since PKA is essential for glucose-mediated remodeling of I~Ba~ in arterial myocytes and can be activated downstream of P2Y~11~ ([@bib60]; [@bib68]), we also examined its involvement in NF546-mediated potentiation of LTCC activity in arterial myocytes. Consistent with a key role for PKA, NF546 failed to upregulate I~Ba~ in arterial myocytes incubated with the PKA inhibitors PKI (100 nM) or rpcAMP (10 μM) ([Figure 7D](#fig7){ref-type="fig"}).

![The P2Y~11~ agonist NF546 increases Ser^1928^ phosphorylation, LTCC activity, and induces vasoconstriction.\
(**A**) Representative I~Ba~ recordings from the same cell (*top*) and summary I~Ba~ data (*bottom*) from freshly dissociated human arterial myocytes in response to step depolarizations from −70 to +10 mV before and after application of 500 nM NF546 (n = 11 cells from five humans; \*p\<0.05, paired *t* test; [Figure 7---source data 1](#fig7sdata1){ref-type="supplementary-material"}). (**B**) Representative I~Ba~ recordings from the same cell (*left)* triggered by step depolarization from −70 mV to voltages ranging from −60 to +60 mV before and after application of 500 nM NF546 in mouse cerebral arterial myocytes and corresponding I~Ba~-voltage relationship (*right*) (n = 8 cells from five mice) (\*p\<0.05, paired *t* test; [Figure 7---source data 2](#fig7sdata2){ref-type="supplementary-material"}). (**C**) Exemplary immunoblot detection of phosphorylated Ser^1928^ (pSer^1928^) and total Ca~V~1.2 from human (*left*) and mouse cerebral and mesenteric arteries (right) incubated with 500 nM NF546 and respective densitometry quantification of pSer^1928^/Ca~V~1.2 ratio (n = 6 arterial lysates per condition for humans; n = 6 arterial lysates per condition for mice) (\*p\<0.05, Wilcoxon matched pairs test; [Figure 7---source data 3](#fig7sdata3){ref-type="supplementary-material"}). (**D**) Representative I~Ba~ recordings from the same cell (top) and summary I~Ba~ data (bottom) from mouse arterial myocytes evoked by step depolarizations from −70 to +10 mV before and after application of 500 nM NF546 in the absence (n = 9 cells, four mice) and presence of 100 nM PKI (n = 9 cells, five mice) or 10 µM rpcAMP (n = 9 cells, four mice) (\*p\<0.05, paired *t* test; [Figure 7---source data 4](#fig7sdata4){ref-type="supplementary-material"}). (**E**) Representative diameter recording and summary arterial tone data from pressurized (60 mmHg) mouse cerebral arteries exposed to 500 nM NF546 (n = 6 arteries, six mice) (\*p\<0.05, Wilcoxon matched pairs test; [Figure 7---source data 5](#fig7sdata5){ref-type="supplementary-material"}). (**F**) Representative diameter recordings and summary arterial tone data from pressurized (60 mmHg) wt mouse cerebral arteries exposed to 20 mM D-glucose before and after application of 500 nM NF546 (n = 6 arteries, six mice, *left*; \*p\<0.05, Friedman with Dunn's multiple comparisons; [Figure 7---source data 6](#fig7sdata6){ref-type="supplementary-material"}) and S9128A mouse cerebral arteries after NF546 application (n = 4 from three mice, right; [Figure 7---source data 6](#fig7sdata6){ref-type="supplementary-material"}).\
10.7554/eLife.42214.057Figure 7---source data 1.Excel spreadsheet containing the individual numeric values of current density analyzed in [Figure 7A](#fig7){ref-type="fig"}.\
10.7554/eLife.42214.058Figure 7---source data 2.Excel spreadsheet containing the individual numeric values of current density analyzed in [Figure 7B](#fig7){ref-type="fig"}.\
10.7554/eLife.42214.059Figure 7---source data 3.Excel spreadsheet containing the individual numeric values of pSer^1928^/Ca~V~1.2 relative density analyzed in [Figure 7C](#fig7){ref-type="fig"}.\
10.7554/eLife.42214.060Figure 7---source data 4.Excel spreadsheet containing the individual numeric values of current density analyzed in [Figure 7D](#fig7){ref-type="fig"}.\
10.7554/eLife.42214.061Figure 7---source data 5.Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in [Figure 7E](#fig7){ref-type="fig"} and corresponding raw diameters.\
10.7554/eLife.42214.062Figure 7---source data 6.Excel spreadsheet containing the individual numeric values of % arterial tone analyzed in [Figure 7F](#fig7){ref-type="fig"} and corresponding raw diameters.](elife-42214-fig7){#fig7}

Having established that application of the P2Y~11~ agonist NF546 influences Ser^1928^ phosphorylation state as well as LTCC activity, we investigated whether it could also modulate arterial tone. Accordingly, pressurized (60 mmHg) arteries that developed stable arterial tone and responded to 60 mM K^+^ ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}) showed significant constriction upon NF546 application ([Figure 7E](#fig7){ref-type="fig"}). Interestingly, NF546 did not induce further constriction in wt arteries previously exposed to 20 mM D-glucose ([Figure 7F](#fig7){ref-type="fig"}). Indeed, arterial tone was similar in arteries treated with 20 mM D-glucose or 20 mM D-glucose +NF546 ([Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). Confirming a critical role for Ser^1928^, arteries from a S1928A knockin mouse in which phosphorylation of this Ca~V~1.2 amino acid is prevented ([@bib48]; [@bib68]; [@bib73]), failed to constrict to NF546 ([Figure 7F](#fig7){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). Response of S1928A arteries to 60 mM K^+^ was similar to those observed for wt arteries ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}). These results suggest that a P2Y~11~ agonist can induce Ser^1928^ phosphorylation, PKA-dependent LTCC potentiation and vasoconstriction, thus recapitulating glucose effects ([@bib60]; [@bib68]), and providing further evidence of the involvement of human P2Y~11~ and mouse P2Y~11~-like receptors in these alterations.

Increased Ser^1928^ phosphorylation and LTCC activity during chronic diabetic hyperglycemia are prevented by a P2Y~11~ inhibitor {#s2-6}
--------------------------------------------------------------------------------------------------------------------------------

To explore whether a P2Y~11~ inhibitor could prevent changes in Ser^1928^ phosphorylation and LTCC activity during chronic diabetic hyperglycemia, we exposed isolated arteries for 48 hr to 10 mM D-glucose, 20 mM mannitol, 20 mM D-glucose or 20 mM D-glucose +NF340. This organ culture method prevents arterial myocyte phenotypic changes associated with prolonged culturing conditions. Furthermore, the exposure time is sufficient to induce many of the vascular remodeling phenomena associated with elevated glucose in arterial myocytes, including increased LTCC activity, decreased K^+^ channel activity and downstream activation of Ca^2+^-dependent transcription factors ([@bib60]; [@bib61]; [@bib64]; [@bib67]; [@bib68]). LTCC function was assessed by measuring single-channel activity using the cell-attached configuration from dissociated arterial myocytes under each experimental condition described above. We found that wt cells isolated from the 20 mM D-glucose but not the 20 mM mannitol treated group had significantly enhanced LTCC open probability (nP~o~) compared to those in the 10 mM D-glucose group ([Figure 8A and B](#fig8){ref-type="fig"}). This increase in LTCC activity during diabetic hyperglycemia, however, was prevented in arterial myocytes from arteries treated in the presence of the P2Y~11~ inhibitor NF340. Ser^1928^ phosphorylation was significantly elevated in arteries chronically exposed to 20 mM D-glucose, but this effect was completely abolished in the presence of NF340 ([Figure 8C](#fig8){ref-type="fig"} and [Figure 8---figure supplement 1A](#fig8s1){ref-type="fig"}). Consistent with a key role for Ser^1928^ phosphorylation in potentiation of LTCC activity in response to chronic elevations in glucose, LTCC nP~o~ was similar in arterial myocytes from S1928A arteries incubated for 48 hr in 10 mM or 20 mM D-glucose ([Figure 8---figure supplement 1B](#fig8s1){ref-type="fig"}). These results suggest that treatment with a P2Y~11~ inhibitor can avert PKA-mediated Ser^1928^ phosphorylation and stimulated LTCC activity during diabetic hyperglycemia.

![Augmented LTCC activity and Ser^1928^ phosphorylation in response to chronic extracellular glucose elevations are prevented in the presence of the P2Y~11~ antagonist NF340.\
(**A**) Representative single LTCC recordings obtained during a 2 s step depolarization from −80 to −30 mV and (**B**) bar plot of LTCC nP~o~ in arterial myocytes isolated from mouse cerebral arteries incubated for 48 hr in 10 mM D-glucose (n = 10 cells from three mice), 20 mM mannitol (n = 13 cells from four mice), 20 mM D-glucose (n = 10 cells from four mice) and 20 mM D-glucose +10 µM NF340 (n = 10 cells from four mice). Channel openings (o) are represented by downward deflections from baseline (c) (\*p\<0.05, one-way ANOVA with Tukey post hoc test; [Figure 8---source data 1](#fig8sdata1){ref-type="supplementary-material"}). (**C**) Representative immunoblot detection of phosphorylated Ser^1928^ (pSer^1928^) and total Ca~V~1.2 from mouse cerebral and mesenteric arteries incubated for 48 hr in 10 mM D-glucose, 20 mM D-glucose and 20 mM D-glucose +10 µM NF340 and densitometry quantification of pSer^1928^/Ca~V~1.2 ratio (n = 7 arterial lysates per condition) (\*p\<0.05, Kruskal-Wallis with Dunn's multiple comparisons; [Figure 8---source data 2](#fig8sdata2){ref-type="supplementary-material"}). (**D**) Proposed model for the role of P2Y~11~ in PKA-dependent stimulation of LTCC activity and vasoconstriction during diabetic hyperglycemia (NUC = nucleotides).\
10.7554/eLife.42214.066Figure 8---source data 1.Excel spreadsheet containing the individual numeric values of LTCC nP~o~ analyzed in [Figure 8B](#fig8){ref-type="fig"}.\
10.7554/eLife.42214.067Figure 8---source data 2.Excel spreadsheet containing the individual numeric values of pSer^1928^/Ca~V~1.2 relative density analyzed in [Figure 8C](#fig8){ref-type="fig"}.](elife-42214-fig8){#fig8}

Discussion {#s3}
==========

Increased arterial myocyte contractility and vasoconstriction in response to elevated extracellular glucose contribute to vascular complications in diabetes ([@bib16]; [@bib29]; [@bib40]; [@bib54]; [@bib61]; [@bib68]). This endothelium-independent component is attributed, at least in part, to glucose-induced decreases in K^+^ channel expression and activity ([@bib40]; [@bib61]; [@bib62]; [@bib63]; [@bib67]; [@bib77]), transcriptional remodeling through NFATc3 signaling ([@bib61]; [@bib63]; [@bib64]; [@bib67]), and alterations in PKC/Rho kinase signaling ([@bib1]; [@bib39]; [@bib44]). Our group has additionally established, in human and mouse arterial tissue, PKA-mediated potentiation of LTCC activity via increased phosphorylation of the pore-forming Ca~V~1.2 subunit at Ser^1928^ as a key event that contributes to vascular complications during diabetic hyperglycemia ([@bib56]; [@bib60]; [@bib68]). The classic molecular machinery stimulating PKA activity implicates activation of upstream effector enzymes (e.g. AC) and G protein-coupled receptors (GPCR). In the present study, using native human arteries and arterial myocytes, we identified a G~s~-coupled P2Y receptor with the molecular, pharmacological, and signaling properties of P2Y~11~ as the GPCR underlying the glucose triggering cascade that results in PKA-dependent potentiation of LTCCs ([Figure 8D](#fig8){ref-type="fig"}). Indeed, P2Y~11~ is known to associate with ACs to stimulate cAMP/PKA signaling ([@bib14]; [@bib71]). Similar results were observed in mouse arteries and arterial myocytes, indicating that a P2Y~11~-like receptor could be mediating the glucose response in these cells. The implications of these observations are profound, as they may shed light on unique mechanisms of diabetic vascular complications.

Elevations in extracellular glucose have been shown to promote autocrine release of nucleotides in a number of cells, including arterial myocytes ([@bib17]; [@bib37]; [@bib64]; [@bib69]). This glucose-induced release of nucleotides has been associated with increased global \[Ca^2+^\]~i~ in arterial myocytes, but the mechanisms and functional implications were not clearly established ([@bib64]). This prompted us to examine whether extracellular nucleotides could be mediating glucose effects on LTCC activity and vascular reactivity. Our first major finding was that hydrolysis of extracellular nucleotides by the ectonucleotidase apyrase prevented the increases in Ser^1928^ phosphorylation, LTCC activity and vasoconstriction in response to elevations in extracellular glucose ([Figure 1](#fig1){ref-type="fig"}). Outcomes from LTCC recordings under continuous flow or static bath conditions ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}) further support the involvement of extracellular nucleotide signaling in mediating the glucose effects. Given the well-established function of extracellular nucleotides in activating P2Y receptors (see ([@bib80])), our studies also pointed to the potential contribution of at least one of the eight known P2Y receptors in this process. In line with this concept, our multidisciplinary approach using human tissue suggested involvement of a P2Y receptor fitting the profile for the P2Y~11~ subtype. Intriguingly, similar results were observed using mouse tissue/cells, suggesting a role for a P2Y~11~-like receptor. To date, this is the only G~s~-coupled P2Y, which could activate AC, leading to increased cAMP synthesis and thereby PKA activation. Considering the essential actions of PKA on LTCC activity and vasoconstriction in response to elevated glucose ([@bib56]; [@bib60]; [@bib68]), we submit that such changes may proceed through activation of this purinergic signaling pathway.

Few studies have examined the role of P2Y~11~ in the cardiovascular system. Current knowledge suggests that this receptor is associated with positive inotropic effects of ATP on cardiomyocytes and its activity seems to be impaired during cardiomyopathy ([@bib5]). Moreover, a polymorphism (Ala-87-Thr) in P2Y~11~ has been linked to increased risk of acute myocardial infarction and C-reactive protein blood levels ([@bib3]). These results indicate a role for P2Y~11~ in cardiac (dys)function. However, the functional significance of P2Y~11~ in the vasculature, and particularly in arterial myocytes, is virtually unknown. In the present study, Western blot analysis detected an immunoreactive band of the expected molecular weight for P2Y~11~ (e.g. \~40 ± 10 kDa) in human arterial lysates ([Figure 2C](#fig2){ref-type="fig"}). We confirmed robust distribution of the receptor at the expected plasma membrane location in isolated human arterial myocytes ([Figure 2D](#fig2){ref-type="fig"}). In line with the expected function for this GPCR, we corroborated localized subplasmalemmal cAMP synthesis upon receptor stimulation with a highly selective P2Y~11~ agonist (NF546 ([@bib52]); [Figure 5](#fig5){ref-type="fig"}). Notably, 20 mM D-glucose triggered cAMP synthesis of the same magnitude as the NF546 compound, and simultaneous application of NF546 and 20 mM D-glucose did not have any additional effect when compared with individual treatment exposure, suggesting that both stimuli proceed through the same signaling pathway. In support of this possibility, the specific P2Y~11~ antagonist NF340 ([@bib52]) blocked the NF546 and NF546 + 20 mM D-glucose effects on cAMP synthesis ([Figure 5](#fig5){ref-type="fig"}). The P2Y~11~ antagonist also prevented increased Ser^1928^ phosphorylation and LTCC activity in response to acute elevations in extracellular glucose ([Figure 6](#fig6){ref-type="fig"}), while the P2Y~11~ agonist NF546 recapitulated all the glucose-induced, PKA-dependent effects ([Figure 7](#fig7){ref-type="fig"}). Moreover, the NF340 compound hampered glucose-induced changes in Ser^1928^ phosphorylation levels and LTCC activity during chronic hyperglycemic conditions resembling those observed during diabetes ([Figure 8](#fig8){ref-type="fig"}). Altogether, these results revealed a role for human P2Y~11~ or mouse P2Y~11~-like receptor in arterial myocytes, particularly during glucose signaling, and suggest that this GPCR may be involved in the initiation and/or progression of arterial myocyte dysfunction leading to vascular complications during diabetic hyperglycemia. Our results may also have profound clinical implications as they add to a growing body of evidence implicating a role for altered P2Y~11~ function in a number of pathological conditions ([@bib66]), which could make them a potential therapeutic target.

Our findings indicating that elevated extracellular glucose triggers PKA-dependent potentiation of LTCC activity to induce vasoconstriction were unexpected, as PKA activity has been traditionally associated with vasodilation due, in part, to increased K^+^ channel activity. A reasonable prediction was that glucose could influence LTCCs via a cAMP/PKA signaling pathway that is distinct from that governing K^+^ channels as occurs upon β adrenergic stimulation ([@bib55]). Such separation in cAMP would require precise subsarcolemmal compartmentalization of key proteins and signaling molecules (including GPCR, signaling enzyme, second messenger, effector protein and substrate). In the case of PKA-dependent effects on LTCC function in response to elevated glucose, this separation would include seclusion of a G~s~-coupled receptor, AC, PKA and Ca~V~1.2. Indeed, *Tajada et al* recently showed that optimal ion channel regulation by effector proteins is constrained by their nanometer distance between each other ([@bib78]). In support of this possibility, our recent work revealed nanometer proximity of a subpopulation of Ca~V~1.2 (\~10% of Ca~V~1.2 clusters) to pools of PKA ([@bib68]). Here, we found a close association (≤40--90 nm) between pools of P2Y~11~ and Ca~V~1.2 as well as P2Y~11~ and PKA ([Figure 3](#fig3){ref-type="fig"}). Moreover, given the cAMP biosensor data demonstrating that both glucose and the P2Y~11~ agonist NF546 induce localized subsarcolemmal cAMP synthesis ([Figure 5](#fig5){ref-type="fig"}), it is also likely that P2Y~11~ may be in close proximity to a specific AC isoform in arterial myocytes - the identity of which remains to be established. Nevertheless, this implicates the formation of a distinctive nanomolecular domain likely containing P2Y~11~, AC, PKA and Ca~V~1.2 in arterial myocytes ([Figure 8D](#fig8){ref-type="fig"}), although its confirmation is beyond the scope of this study. This nanodomain may ensure the necessary signaling compartmentalization required for PKA-mediated effects on LTCC activity and vascular reactivity in response to elevated glucose.

The spatial organization of the P2Y~11~/AC/PKA/Ca~V~1.2 nanodomain could be facilitated by scaffold proteins, such as A kinase anchoring proteins (AKAPs). These AKAPs fine tune signal transduction by localizing GPCRs, signaling enzymes and effector proteins in close proximity to their substrates ([@bib41]; [@bib47]). The A kinase anchoring protein 150 (AKAP150; murine ortholog of human AKAP79) is of particular interest as it has been shown to interact with AC, PKA and Ca~V~1.2 ([@bib8]; [@bib28]; [@bib33]; [@bib57]; [@bib58]; [@bib68]; [@bib84]). Intriguingly, although AKAP79/150 can associate with multiple GPCRs ([@bib31]; [@bib83]), no report to date has linked it to any purinergic receptor. Localization of P2Y~11~ within the same AKAP79/150-driven complex may be critical as this scaffold protein is necessary for increased L-type Ca^2+^ channel activity in response to elevated glucose ([@bib68]). Two possibilities that do not exclude a fundamental role for AKAP79/150 are 1) direct interaction of P2Y~11~ with the scaffold protein and/or 2) association of the receptor with a pool of Ca~V~1.2 within the AKAP79/150 complex. Future studies should examine these exciting alternatives as they may provide further insight into mechanisms regulating LTCCs and vascular reactivity during diabetic hyperglycemia.

A lingering question is how nucleotides, such as ATP, are released in response to glucose to modulate arterial myocyte excitability. Although our data do not identify the specific nucleotide, ATP release is particularly interesting as this nucleotide is an effective vasoactive agent and the endogenous P2Y~11~ agonist ([@bib14]; [@bib42]; [@bib75]; [@bib80]). Indeed, ATP can activate P2Y~11~ with an EC~50~ that ranges from 1.8 to 17 μM, depending on the readout and the cell type used ([@bib15]; [@bib34]; [@bib52]; [@bib72]). Moreover, P2Y~11~ can be activated by ATP/ATP-derived nucleotides with the following potency order: ATPγS \> dATP \> ATP\>\>\>ADP, with other nucleotides such as UTP and UDP having minimal or no influence on receptor activation ([@bib42]; [@bib75]; [@bib80]). Our recent study suggested that glucose effects on LTCC activity and vascular reactivity require glucose transport into the cell and subsequent metabolism that can generate ATP ([@bib68]). ATP can then be transported out of the cell through ATP-binding cassettes, vesicular exocytosis, plasma membrane F~1~F~0~-ATPase, connexin hemichannels and pannexin channels to induce activation of P2Y~11~ ([@bib50]). We thus speculate that one of these ATP transporters could form part of the AKAP/P2Y~11~/AC/PKA/Ca~V~1.2 nanocomplex to provide another layer of compartmentalization that facilitates PKA-dependent regulation of LTCC function and vascular reactivity in response to elevations in extracellular glucose.

In summary, our data in human and murine tissue provide evidence of a G~s~-coupled purinergic receptor that fits the profile of P2Y~11~ or a P2Y~11~-like receptor, respectively, as a key upstream component in the signaling cascade regulating LTCC activity and vascular reactivity during diabetic hyperglycemia. Data start to define a unique nanomolecular complex likely formed by AKAP/P2Y~11~/AC/PKA/Ca~V~1.2. This nanocomplex can organize glucose signaling and help explain the intriguing consequences of glucose-induced PKA activation on LTCC function and vascular reactivity, which may have significant pathological implications, and therapeutic potential to treat vascular complications during diabetic hyperglycemia.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent\                          Designation                                                      Source or reference           Identifiers                                                                                                              Additional\
  type (species)\                                                                                                                                                                                                                                           information
  or resource                                                                                                                                                                                                                                               
  --------------------------------- ---------------------------------------------------------------- ----------------------------- ------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------
  Strain\                           wild-type                                                        Jackson Laboratories          stock \# 000664                                                                                                          
  (*Mus musculus*),\                                                                                                                                                                                                                                        
  C57BL/6J                                                                                                                                                                                                                                                  

  Strain\                           S1928A                                                           ([@bib48])                                                                                                                                             
  (*Mus musculus*)                                                                                                                                                                                                                                          

  Cell line\                        tsA-201                                                          Sigma-Aldrich                 96121229                                                                                                                 SV40 transformed
  (human\                                                                                                                                                                                                                                                   
  embryonal\                                                                                                                                                                                                                                                
  kidney)                                                                                                                                                                                                                                                   

  Oligodeoxynucleotide, sense       P2Y~11~ SNS ODN                                                  Integrated DNA Technologies   human P2Y~11~ sequence\                                                                                                  last three bases on the 3' end were phosphoro-thioated
                                                                                                                                   (NC_000019.10): 5'-CAACGTCTCGGGTAAGGAGAA-3' and 5'-ATGAGGAAGGAAACGTGGGT-3'                                               

  Oligodeoxynucleotide, antisense   P2Y~11~ ANS ODN                                                  Integrated DNA Technologies   human P2Y~11~ sequence\                                                                                                  last three bases on the 3' end were phosphoro-thioated
                                                                                                                                   (NC_000019.10): 5'-CAAGGCCACCCTAACCACTG-3'\                                                                              
                                                                                                                                   and 5'-CTCTCCCTTCCCTGCGTTA-3'                                                                                            

  DNA construct                     human P2Y~11~                                                    UMR cDNA\                     [www.cDNA.org](http://www.cDNA.org); clone ID\                                                                           tagged with GFP at C-\
                                                                                                     Resource Center               P2Y1100000                                                                                                               terminus

  Antibody                          anti-FP1 (Ca~V~1.2; custom rabbit)                               ([@bib19])                                                                                                                                             dilutions: 1:100 for\
                                                                                                                                                                                                                                                            immunoblot and PLA;\
                                                                                                                                                                                                                                                            10 µg/mL for GSD

  Antibody                          anti-CH3P\                                                       ([@bib19])                                                                                                                                             1:50-1:100 dilutions
                                    (pSer^1928^,\                                                                                                                                                                                                           
                                    custom rabbit)                                                                                                                                                                                                          

  Antibody                          anti-β-actin (mouse monoclonal)                                  Abcam                         ab8226\                                                                                                                  1:1000 dilution
                                                                                                                                   RRID: [AB_30637](https://scicrunch.org/resolver/AB_30637)                                                                

  Antibody                          anti-α-tubulin (mouse monoclonal)                                Active Motif                  39527; clone 5-B-1--2                                                                                                    1:500 dilution

  Antibody                          anti-P2Y~11~ (rabbit polyclonal)                                 Abcam                         ab180739                                                                                                                 1:100-1:200 dilutions

  Antibody                          anti-P2Y~11~ (goat polyclonal)                                   Santa Cruz\                   sc-69588; clone C-18\                                                                                                    dilutions: 1:100 for\
                                                                                                     Biotechnology                 RRID: [AB_21559](https://scicrunch.org/resolver/AB_21559)                                                                stainings (PLA,\
                                                                                                                                                                                                                                                            classical) and 10 µg/mL\
                                                                                                                                                                                                                                                            for GSD

  Antibody                          anti-PKA~cat~α, β, γ (mouse\                                     Santa Cruz\                   sc-28315; clone A-2                                                                                                      1:200 dilution
                                    monoclonal)                                                      Biotechnology                                                                                                                                          

  Antibody                          PKA~cat~α, β, γ blocking peptide                                 Santa Cruz\                   sc-28315 P; clone A-2                                                                                                    1:20 dilution for 1 µg of primary\
                                                                                                     Biotechnology                                                                                                                                          antibody

  Antibody                          anti-PKA~cat~ α, β, γ (rabbit polyclonal)                        Santa Cruz Biotechnology      sc-28892; clone H-95                                                                                                     dilutions: 1:200 for PLA and 10 µg/mL for GSD

  Antibody                          Alexa Fluor 488 conjugate of wheat germ agglutinin               Life Technologies             W7024                                                                                                                    

  Antibody                          Alexa Fluor 568-conjugated donkey anti-goat                      Molecular Probes              A11057\                                                                                                                  5 mg/mL dilution
                                                                                                                                   RRID: [AB_142581](https://scicrunch.org/resolver/AB_142581)                                                              

  Antibody                          Alexa Fluor 568-conjugated donkey anti-mouse                     Molecular Probes              A10037                                                                                                                   5 mg/mL dilution

  Antibody                          Alexa Fluor 568-conjugated donkey anti-rabbit                    Molecular Probes              A11011\                                                                                                                  2 µg/mL dilution
                                                                                                                                   RRID: [AB_143157](https://scicrunch.org/resolver/AB_143157)                                                              

  Antibody                          Alexa Fluor 647-conjugated donkey anti-goat                      Molecular Probes              A21447\                                                                                                                  2 µg/mL dilution
                                                                                                                                   RRID: [AB_141844](https://scicrunch.org/resolver/AB_141844)                                                              

  Antibody                          goat anti-rabbit IgG (H + L)-horseradish peroxidase conjugate    Bio-Rad                       170--6515\                                                                                                               1:10000 dilution
                                                                                                                                   RRID: [AB_11125142](https://scicrunch.org/resolver/AB_11125142)                                                          

  Antibody                          goat anti-mouse IgG (H + L)-horseradish peroxidase conjugate     Bio-Rad                       170--6516                                                                                                                1:10000 dilution

  Chemical\                         sodium pentobarbital (Fatal-Plus)                                Vortech Pharma-ceuticals      NDC 0298-9373-68                                                                                                         
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         mannitol                                                         Fisher Scientific             BP686                                                                                                                    
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         NF340                                                            Santa Cruz Biotechnology      sc-361274                                                                                                                
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         NF546                                                            Tocris                        3892                                                                                                                     
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         apyrase                                                          New England\                  M0398L                                                                                                                   
  compound,\                                                                                         Biolabs                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         nifedipine                                                       Sigma-Aldrich                 N7634                                                                                                                    
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         Bay K-8644                                                       Sigma-Aldrich                 71145-03-4                                                                                                               
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         forskolin                                                        Sigma-Aldrich                 F6886                                                                                                                    
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         amphotericin B                                                   Sigma-Aldrich                 A4888                                                                                                                    
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         MRS2578                                                          Santa Cruz Biotechnology      sc-204103A                                                                                                               
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         MRS2179                                                          Tocris                        1454889-37-2                                                                                                             
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Chemical\                         protein kinase A inhbitor (PKI)                                  Sigma-Aldrich                 P9115                                                                                                                    fragment\
  compound,\                                                                                                                                                                                                                                                14--22, myristoylated\
  drug                                                                                                                                                                                                                                                      trifluoroacetate salt

  Chemical\                         Rp-Adenosine 3',5'-cyclic\                                       Sigma-Aldrich                 A165                                                                                                                     
  compound,\                        monophos-phorothioate triethylam-monium salt (rpcAMP)                                                                                                                                                                   
  drug                                                                                                                                                                                                                                                      

  Chemical\                         Adenosine 5'-\[γ-thio\] triphosphate tetralithium salt (ATPγS)   Sigma-Aldrich                 A1388                                                                                                                    
  compound,\                                                                                                                                                                                                                                                
  drug                                                                                                                                                                                                                                                      

  Software,\                        GraphPad Prism                                                                                 GraphPad Prism, RRID: [SCR_002798](https://scicrunch.org/scicrunch/Any/record/nlx_144509-1/SCR_002798/resolver?q=*&l=)   
  algorithm                                                                                                                                                                                                                                                 

  Software,\                        ImageJ                                                                                         Fiji,\                                                                                                                   
  algorithm                                                                                                                        RRID: [SCR_002285](https://scicrunch.org/resources/Any/record/nlx_144509-1/SCR_002285/resolver?q=*&l=)                   

  Software,\                        pCLAMP10                                                         Molecular Devices                                                                                                                                      electrophysiology
  algorithm                                                                                                                                                                                                                                                 

  Software,\                        LASAF                                                            Leica                                                                                                                                                  GSD
  algorithm                                                                                                                                                                                                                                                 

  Software,\                        IonOptix                                                         IonOptix                                                                                                                                               arterial diameter\
  algorithm                                                                                                                                                                                                                                                 recordings

  Software,\                        Metaflor                                                         Molecular Devices                                                                                                                                      FRET
  algorithm                                                                                                                                                                                                                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

Male wild type C57BL/6J (wt) or knockin mice in which Ser^1928^ of Ca~V~1.2 was mutated to Ala (S1928A) ([@bib48]) of 5 to 8 weeks of age were euthanized with a lethal dose of sodium pentobarbital (250 mg/kg; intraperitoneally), as approved by the University of California, Davis Animal Care and Use Committee (protocol \#: 20321).

Human tissue {#s4-2}
------------

Excised adipose arteries from human patients undergoing surgical sleeve gastrectomy were used for this study ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). Samples were obtained after Institutional Review Board (IRB) approval from the University of Nevada Reno School of Medicine (IRB ID: 2013--019) and in accordance with the guidelines of the *Declaration of Helsinki*. The need for informed consent was waived by IRBs at the University of Nevada Reno School of Medicine (IRB ID: 2013--019) and the University of California Davis (IRB ID: 597267--1) because the tissue is considered 'waste', has no codification that could be used to identify patients and was determined not to be human subject research in accordance with United States of America federal regulations, as defined by 45 CFR 46.102(f). This precludes the acquisition of detailed clinical profiles other than sex, age and whether the patient is nondiabetic or diabetic. Only samples from nondiabetic patients were used. No exclusions were made due to medication history, sex or presence of comorbidities. Collected tissue was placed in cold phosphate-buffered saline (PBS) solution containing (in mM): 138 NaCl, 3 KCl, 10 Na~2~HPO~4~, 2 NaH~2~PO~4~, 5 D-glucose, 0.1 CaCl~2~, and 0.1 MgSO~4~, pH 7.4 with NaOH until used.

Arterial myocyte isolation {#s4-3}
--------------------------

Mouse cerebral arteries were dissected in ice-cold dissection buffer containing (in mM): 140 NaCl, 5 KCl, 2 MgCl~2~, 10 D-glucose, 10 HEPES, pH 7.4, with NaOH. Arteries were digested in dissection buffer containing papain (1 mg/mL) and dithiothreitol (1 mg/mL) at 37° C for 7 min, followed by incubation in dissection buffer containing collagenase type F (0.7 mg/mL) and collagenase type H (0.3 mg/mL) at 37° C for 7 min. Arteries were washed in ice-cold dissection buffer and gently triturated with glass pipettes to disperse the cells, which were kept in ice-cold dissection buffer until use.

Single human arterial myocytes ([Supplementary file 3](#supp3){ref-type="supplementary-material"}) were isolated as previously described ([@bib62]; [@bib68]). Briefly, small diameter adipose arteries from human samples were enzymatically digested in dissection solution supplemented with papain (26 U/mL) and dithiothreitol (1 mg/mL) at 37° C for 15 min, followed by incubation in dissection solution containing collagenase type H (1.95 U/mL), elastase (0.5 mg/mL), and trypsin inhibitor (1 mg/mL) at 37° C for 10 min. Cells were then washed three times in ice-cold dissection buffer, triturated with glass pipettes to disperse the individual cells, and maintained in ice-cold dissection buffer until use.

For unpassaged, cultured human and mouse arterial myocytes, human adipose arteries and mouse aortas were dissected out and placed in ice-cold Dulbecco's Modified Eagle Medium (DMEM; Gibco -- Life Technologies, Grand Island, NY) containing 1X glutamate, 1X pyruvate, 1X penicillin/streptavidin and fungizone (0.25 g/mL). Artery segments were subsequently transferred and incubated in a DMEM solution containing 2.2 mg/mL of collagenase Type 2 (Worthington) at 37° C for 15 min to remove the adventitia. To disperse and culture unpassaged arterial myocytes, the tissue was cut into 2--5 mm segments and incubated at 37° C with constant shaking in a buffer containing (in mM): 134 NaCl, 6 KCl, CaCl~2~, 10 HEPES, and 7 D-glucose supplemented with 2.2 mg/mL collagenase Type 2 (Worthington). The digestion was stopped by adding an equal volume of DMEM containing 5% fetal bovine serum. Digested tissue was then centrifuged for 5 min at 14,000 rpm. The supernatant was removed and the pellet containing the digested tissue was resuspended in DMEM containing 1X glutamate, 1X pyruvate, 5% serum and 5 mM D-glucose, resulting in dispersion of individual arterial myocytes. Cells were then seeded on glass coverslips coated with laminin and kept in an incubator at 37° C with 5% CO~2~ for 2--3 days before adenoviral transduction or lysis for immunoblotting (see section below).

Arterial diameter measurements {#s4-4}
------------------------------

Freshly isolated posterior mouse cerebral arteries were cannulated on glass micropipettes mounted in a 5 mL myograph chamber (University of Vermont Instrumentation and Model Facility), as described previously ([@bib62]; [@bib67]; [@bib68]). Arteries were allowed to equilibrate at an intravascular pressure of 20 mmHg, while being continuously superfused (37° C, 30 min, 3--5 mL/min) with physiological saline solution composed of (in mM): 119 NaCl, 4.7 KCl, 2 CaCl~2~, 24 NaHCO~3~, 1.2 KH~2~PO~4~, 1.2 MgSO~4~, 0.023 EDTA, and 10 D-glucose aerated with 5% CO~2~/95% O~2~. Bath pH was closely monitored and maintained at 7.35 to 7.4. After equilibration, intravascular pressure was increased to 60 mmHg and arteries allowed to develop stable myogenic tone. Arteries not exhibiting stable tone after \~1 hr were discarded. To assess the response of arterial diameter to hyperglycemia, D-glucose was increased from 10 mM to 20 mM in the perfusion solution. Arterial tone data are presented as a percent decrease in diameter relative to the maximum passive diameter at 60 mmHg obtained using Ca^2+^-free saline solution containing nifedipine (1 µM) at the end of the experiment.

Electrophysiology {#s4-5}
-----------------

All experiments were performed at room temperature (22--25° C). Both whole-cell and single-channel data were acquired using an Axopatch 200B amplifier and Digidata 1440 digitizer (Molecular Devices). Recording electrodes were pulled from borosilicate capillary glass using a micropipette puller (model P-97, Sutter Instruments) and subsequently polished to achieve resistances that ranged from 3.5 to 6.5 MΩ. L-type Ca^2+^ channel currents were assessed in freshly dissociated arterial myocytes using the perforated whole-cell mode of the patch-clamp technique with Ba^2+^ as a charge carrier (I~Ba~) after myocytes were allowed to attach (10 min) to a glass coverslip in a recording chamber. Borosilicate glass pipettes were filled with a solution containing (in mM): 120 CsCl, 20 tetraethylammonium chloride (TEA-Cl), 1 EGTA, and 20 HEPES with amphotericin B (250 µg/mL; pH adjusted to 7.2 with CsOH). The bath solution consisted of (in mM): 115 NaCl, 10 TEA-Cl, 0.5 MgCl~2~, 10 D-glucose, 5 CsCl, 20 BaCl~2~, and 20 HEPES, pH adjusted to 7.4 with CsOH. I~Ba~ were elicited by 200 ms depolarizing pulses from a holding potential of −70 mV to +10 mV. I~Ba~ were first recorded in the presence of 10 mM D-glucose under static flow conditions. This solution was then exchanged for a solution containing either 20 mM D-glucose, 20 mM mannitol or NF546 at a rate of 2.1 mL/min. Flow was stopped after 3 min, and I~Ba~ were recorded again under static flow conditions at least 5 min after the indicated treatment was initiated. In some experiments, arterial myocytes were pretreated for 10--15 min with indicated inhibitors prior to I~Ba~ recordings. For experiments comparing I~Ba~ before and after elevated glucose under continuous flow and static bath conditions, cells were patched in a bath solution containing 10 mM D-glucose at a perfusion rate of 2.1 mL/min. After establishment of a stable gigaseal for at least 5 min, I~Ba~ were recorded in the presence of 10 mM D-glucose under continuous flow. Those cells that showed robust I~Ba~ in 10 mM D-glucose were then perfused with a bath solution containing 20 mM D-glucose under continuous flow for at least 5 min before recording of I~Ba~ again. Subsequently, I~Ba~ were recorded one more time on the same cell, 5 min after stopping the bath perfusion (e.g. static bath conditions). Currents were sampled at 10 kHz and low pass-filtered at 5 kHz. The Ca~V~1.2 blocker nifedipine (1 μM) was applied at the end of each experiment to determine the nifedipine-sensitive component. The I-V relationship of nifedipine-sensitive I~Ba~ was determined by 200 ms depolarizing steps from −70 mV to voltages ranging from −60 to +60 mV in increments of +10 mV. The I-V relationship for averaged data sets was fit with a peak Gaussian function: *I*(*V*)=*I*~max~ x exp(−0.5((*V -- V*~max~)/*b*)^2^), where *I*~max~ is peak *I*, *V*~max~ is *V* at *I*~max~, and *b* is the slope of the distribution, as described previously ([@bib68]). A voltage error of 10 mV attributable to the liquid junction potential of the recording solutions was corrected offline.

The cell-attached configuration of the patch-clamp technique was used to examine single-channel Ca^2+^ currents in arterial myocytes using Ca^2+^ as the charge carrier, as previously described ([@bib13]; [@bib25]; [@bib24]; [@bib59]; [@bib68]). Resting membrane potential was fixed to \~0 mV using a high K^+^ bath solution ([@bib38]; [@bib82]) composed of (in mM): 145 KCl, 10 NaCl, and 10 HEPES, pH adjusted to 7.4 with NaOH. Pipette solution was composed of (in mM): 120 TEA-Cl, 110 CaCl~2~, and 10 HEPES with BayK-8644 (500 nM), which promotes longer open times of the channel thereby increasing the probability of sweeps with channel activity. Single L-type Ca^2+^ currents were elicited by a 2 s depolarizing step from a holding of −70 mV to −30 mV. Single-channel currents were sampled at 10 kHz and low pass filtered at 2 kHz, followed by a Gaussian filter (500 Hz) during analysis. Capacitive currents were compensated by subtraction of blank sweeps. When nifedipine was included in the patch pipette, Ca~V~1.2 activity was negligible. Single-channel openings and nP~o~ were analyzed using the single-channel event half-amplitude detection algorithm from pCLAMP 10.

Immunoprecipitation and immunoblotting {#s4-6}
--------------------------------------

Human adipose arteries, mouse cerebral and mesenteric arteries, and mouse arterial myoyctes were homogenized in a RIPA lysis buffer solution composed of 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EGTA, 10 mM EDTA, 1% nonyl phenoxypolyethoxylethanol-40 (NP-40), 10% glycerol, 0.05% sodium dodecyl sulfate (SDS), 0.4% deoxycholic acid (DOC) with protease inhibitors (1 µg/ml pepstatin A, 10 µg/ml leupeptin, 20 µg/mL aprotinin, and 200 nM phenylmethylsulfonyl fluoride) and phosphatase inhibitors (2 µM microcystin LR, 1 mM *p*-nitrophenyl phosphate, 50 mM Na-pyrophosphate, and 50 mM NaF), then sonicated for 5 min at 4° C and cleared by centrifugation (15,000 X *g)* for 20 min at 4° C. For Ser^1928^ phosphorylation experiments, the soluble fraction was incubated on a head-over-head tilter with protein A-Sepharose beads and a purified custom antibody against Ca~V~1.2 (5 µg of FP1; see [@bib19]) or nonspecific rabbit immunoglobulin G (IgG) control for 4 hr at 4° C. Beads were washed three times with washing buffer containing (in mM): 150 NaCl, 10 EDTA, 10 EGTA, 10 Tris-HCl (pH 7.4), 0.1% Triton X-100, pH 7.4. Samples were extracted in Laemmli Sample Buffer (Bio-Rad) for 5 min at 95° C for immunoprecipitation (Ser^1928^ phosphorylation) experiments and 15 min at 80° C for other immunoblot experiments. Proteins were separated by SDS-polyacrylamide gel electrophoresis at 75--100 V for 1.5 hr in a stacking gel polymerized from 3% acrylamide and a resolving phase polymerized from 7.5% (Ser^1928^ phosphorylation) or 10% acrylamide. Proteins were then transferred to a polyvinylidene difluoride membrane at 50 V for 600 min at 4° C. All membranes, except for P2Y~11~ blots (10% Odyssey blocking buffer; LI-COR Biosciences), were blocked in 5% nonfat dried milk in tris-buffered saline with 0.05% Tween 20 (TBS-T) for 1 hr at room temperature before primary antibody incubation for 2--3 hr at room temperature. Antibodies and dilutions were as follows: rabbit anti-CH3P (pSer^1928^; 1:50-1:100),([@bib19]) rabbit anti-FP1 (Ca~V~1.2; 1:100) ([@bib19]), rabbit anti-P2Y~11~ (Abcam, 1:100-1:200); mouse anti-β-actin (Abcam, 1:1000), and anti α-tubulin (Active Motif, 1:500). Except for the P2Y~11~ antibody, which was diluted in 1% bovine serum albumin, all antibodies were diluted in 5% nonfat dried milk in TBS-T. After washing, membranes were then incubated 1 hr at room temperature with horseradish peroxidase-labeled goat anti-rabbit (Bio-Rad; 1:10,000) or goat-anti-mouse antibodies (Bio-Rad; 1:10,000) diluted in 5% nonfat dried milk in TBS-T or 5% Odyssey in TBS-T (P2Y~11~ only) and developed on autoradiography film using chemiluminescence (Classico \[Millipore\] and Femto \[Thermo Fisher Scientific\]). For Ser^1928^ phosphorylation and P2Y~11~ knock down experiments, total Ca~V~1.2 and β-actin, respectively, were used for normalization (density expressed as percentage of total Ca~V~1.2/β-actin and these ratios were normalized to the ratio of the control band to get the relative density of pSer^1928^/Ca~V~1.2 or P2Y~11~/β-actin for all treatments). For Ser^1928^ phosphorylation quantification in [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}, triplicates were run in parallel and all values were normalized to the ratio of the loading control band (e.g. α-tubulin obtained from the same samples) to get the pSer^1928^/α-tubulin ratio for all treatments. The pSer^1928^/α-tubulin ratios were then normalized to the first control band ratio to obtain the relative density of pSer^1928^/α-tubulin. Densitometry analysis for bands was performed with ImageJ software (National Institutes of Health) as follow. Developed films were scanned to tiff files, uploaded to ImageJ and color inverted. Immunoreactive bands were outlined and light intensity per area was measured. Doublet bands were outlined and measured as one signal. Intensity of equal area above and below each immunoreactive band was measured to average and then subtract the background signal. Importantly, films were exposed for increasing time periods to ensure signals were in the linear range as described in [@bib20] and [@bib35]. β-actin and α-tubulin were used as a loading control in some experiments.

Organ culture {#s4-7}
-------------

Freshly isolated arteries for acute Ser^1928^ phosphorylation experiments were incubated for 5 min at room temperature in a physiological saline solution composed of (in mM): 119 NaCl, 4.7 KCl, 2 CaCl~2~, 24 NaHCO~3~, 1.2 KH~2~PO~4~, 1.2 MgSO~4~, 0.023 EDTA, and 10 (5 for humans) D-glucose aerated with 5% CO~2~/95% O~2~ to reach a pH of 7.35--7.4. Arteries were then incubated for 10 min at room temperature in a similar physiological solution containing the specified treatment. Following incubation, arteries were immediately placed in RIPA lysis buffer with protease and phosphatase inhibitors (as described in immunoblotting section). For chronic exposure experiments, arteries were placed in DMEM/F-12 (Gibco-Life Technologies, Grand Island, NY) supplemented with L-glutamine (2 mM) containing 10 mM, 20 mM D-glucose or 20 mM mannitol in the absence or presence of 10 µM NF340 and incubated for 48 hr at 37° C. After incubation, arteries were quickly washed in PBS and then placed in RIPA lysis buffer with protease and phosphatase inhibitors for immunoblotting.

Immunofluorescence {#s4-8}
------------------

Immunofluorescent labeling of freshly dissociated arterial myocytes was performed as described previously ([@bib58]), using a goat-anti P2Y~11~ (Santa Cruz Biotechnology, clone C-18; 1:100) or a mouse-anti PKA~cat~ α, β, γ (Santa Cruz Biotechnology, clone A-2, 1:200) antibodies in PBS supplemented with 0.1% BSA. Alexa Fluor 488 conjugated wheat germ agglutinin (WGA; Life Technologies) was used to stain for the plasma membrane. The secondary antibodies were Alexa Fluor 568-conjugated donkey anti-goat and donkey anti-mouse (5 mg/mL; Molecular Probes). In control experiments, the PKA~cat~ antibody was preabsorbed with a PKA~cat~ blocking peptide (Santa Cruz Biotechnology, A-2; 1:20 for 1 μg of primary antibody). Cells were imaged (512 × 512 pixel images) using an Olympus FV1000 confocal microscope paired with an Olympus 60x oil immersion lens (NA = 1.4) and a zoom of 3.0 (pixel size = 0.1 µm). P2Y~11~-associated fluorescence was not detected in negative control experiments in which the primary antibody was substituted for PBS or boiled to test for antibody specificity. Cells for each group were imaged with the same laser power, gain settings, and pinhole.

Proximity ligation assay {#s4-9}
------------------------

A Duolink In Situ PLA kit (Sigma) ([@bib32]) was used to detect complexes consisting of P2Y~11~ and Ca~V~1.2 and P2Y~11~ and PKA~cat~ in freshly isolated arterial myocytes as previously described ([@bib62]; [@bib68]). Briefly, cells were plated on glass coverslips and allowed to adhere (1 hr, room temperature) prior to fixing with 4% paraformaldehyde (20 min), quenching in 100 mM glycine (15 min), and washing in PBS (2 × 3 min). Cells were permeabilized with 0.1% Triton X-100 (20 min) and then blocked (1 hr, 37° C) in 50% Odyssey blocking solution (LI-COR Bioscience). Cells were incubated overnight at 4° C with a specific combination of two primary antibodies in 0.1% Odyssey +0.05% Triton X-100 PBS solution: goat anti-P2Y~11~ (Santa Cruz Biotechnology, clone C-18; 1:100), custom rabbit anti-FP1 (Ca~V~1.2, 1:100) ([@bib19]) and rabbit anti-PKA~cat~ α, β, γ (Santa Cruz Biotechnology, clone H-95, 1:200). Cells were incubated with only one primary antibody as negative controls. After primary antibody incubation, cells were washed with Duolink buffer A (2 × 5 min). Oligonucleotide-conjugated secondary antibodies (PLA probes: anti-goat MINUS and anti-rabbit PLUS) were used to detect P2Y~11~ and Ca~V~1.2 and P2Y~11~ and PKA~cat~ (1 hr, 37° C). Following incubation with probes, cells were washed with Duolink buffer A (2 × 5 min) and a ligation solution composed of two distinct oligonucleotides, complementary to the probes, and ligase was added (30 min, 37° C) to allow hybridization with the probes and formation of a closed DNA circle at sites of dual labeling, which serves as a template for a rolling circle amplification reaction (100 min, 37° C). After the amplification step, cells were washed with Duolink buffer B (2 × 10 min) and 1% buffer B (1 × 1 min). Coverslips were allowed to dry and subsequently mounted on a microscope slide with Duolink mounting medium. The fluorescence signal was detected using an Olympus FV1000 confocal microscope coupled with a 60x oil immersion lens (NA, 1.4). Images were collected at different optical planes (*z*-axis step = 0.5 µm). The stack of images for each sample was combined into a single-intensity projection image that was subsequently used for analysis of number of puncta/µm^2^ per cell.

Immunolabeling and Ground State Depletion (GSD) microscopy {#s4-10}
----------------------------------------------------------

Isolated arterial myocytes were allowed to adhere to a coverslip (1 hr) before fixing with 3% paraformaldehyde +0.1% glutaraldehyde solution in PBS (10 min) followed by washes with PBS (3 × 15 min). Cells were then incubated for 5 min with 0.1% sodium borohydride in H~2~O, followed by 3 × 5 min washes with PBS and incubated in permeabilization/blocking solution consistent of 0.05% Triton X-100% and 20% SEA BLOCK (Thermo Scientific) for 1 hr at room temperature. Cells were exposed overnight to primary antibodies \[goat anti-P2Y~11~ (Santa Cruz Biotechnology, clone C-18), custom rabbit anti-Ca~V~1.2 (FP1 ([@bib19])) or rabbit anti-PKA~cat~ α, β, γ (Santa Cruz Biotechnology, clone H-95)\] diluted in blocking buffer to a concentration of 10 µg/mL. Cells were briefly washed 3x with PBS, followed by additional longer washes (3x for 15 min). For secondary antibodies, donkey Alexa Fluor 647-conjugated antibody recognizing goat IgG (2 µg/mL; Molecular Probes) and donkey Alexa Fluor 568-conjugated antibody recognizing rabbit IgG (2 µg/mL; Molecular Probes) diluted in blocking buffer were added for 1 hr at room temperature. Secondary Ab was washed 3x with PBS, followed by longer washes (3x for 15 min). Specificity of secondary antibodies was tested in control experiments in which primary antibodies were omitted from the preparation (no 1° antibody controls). For imaging, coverslips were mounted on microscope slides with a round cavity containing MEA-GLOX imaging buffer (NeoLab Migge Laborbedarf-Vertriebs GmbH, Germany) and sealed with Twinsil (Picodent, Germany). The imaging buffer was composed of 10 mM MEA (cysteamine), 0.56 mg/mL glucose oxidase, 34 µg/mL catalase, and buffer containing 10% w/v glucose, 10 mM NaCl, and 50 mM Tris-HCl, pH 8.

Super-resolution images of arterial myocytes were obtained using a super resolution ground state depletion system (SR-GSD, Leica) dependent on stochastic single-molecule localization, equipped with high-power lasers (532 nm, 2.1 kW/ cm^2^; 642 nm, 2.1 kW/ cm^2^) and an additional 30 mW, 405 nm laser. A 160x HCX Plan-Apochromat (NA 1.47) oil immersion lens and an electron-multiplying charge-coupled device (EMCCD) camera (iXon3 897; Andor Technology) were used to acquire images ([@bib25]). The camera was running in frame-transfer mode at a frame rate of 100 Hz (10 ms exposure time). Fluorescence was detected through Leica high-power TIRF filter cubes (532 HP-T, 642 HP-T) with emission band-pass filters of 550--650 nm and 660--760 nm. Reconstruction of P2Y~11~, Ca~V~1.2, and PKA distribution from 30,000 images used the coordinates of centroids obtained by fitting single-molecule fluorescence signals with a 2D Gaussian function using a LASAF software (Leica). The localization accuracy of the system is limited by the statistical noise of photon counting; the precision of localization is proportional to DLR/√N, where DLR is the diffraction-limited resolution of a fluorophore and N is the average number of detected photons per switching event, assuming the point-spread functions are Gaussian ([@bib23]; [@bib30]). The full width at half maximum for single-molecule signals was \~20 nm as recently calculated by our group ([@bib78]). Localizations produced from less than 800 photons were filtered out of the reconstruction. All pixels with intensity above a user-defined threshold were binarized, evaluated and segmented into individual objects and included as clusters in our analysis. Cluster size and density were determined using the Analyze Particle option in the ImageJ software (National Institute of Health). The JACoP plug-in in the ImageJ software was used to unbiasedly and automatically determine the shortest intermolecular distances for P2Y~11~ and Ca~V~1.2 as well as P2Y~11~ and PKA~cat~ following the protocol described by [@bib9]. Intermolecular distance histograms were generated from the JACoP plug-in output data and fitted with a sum of two Gaussian functions of the following equation: *Y* =*Y~0~* + (*A~1~* / (*w~1~* x √(*π/2*))) x exp(−2 x ((*X - X~C1~*)/*w~1~*)^2^) + (*A~2~* / (*w~2~* x √(*π/2*))) x exp(−2 x ((*X - X~C2~*)/*w~2~*)^2^), where *Y~0~* is the *Y* offset, *A~1~* and *A~2~* are the areas of the distribution of distances, *X~C1~* and *X~C2~* are the x values of distance at the center of the distribution, and *w~1~* and *w~2~* are the widths of each distribution in nanometers. To calculate the percentage of complete P2Y~11~ overlap, we first quantified the number of clusters/objects in the thresholded, binarized localization maps for P2Y~11~ and Ca~V~1.2 as well as P2Y~11~ and PKA~cat~ using the Analyze Particle tool in ImageJ. The binarized localization maps of P2Y~11~ were then multiplied by those corresponding to the paired Ca~V~1.2 or PKA~cat~ localization maps. The number of objects obtained from this operation were then divided by the number of clusters/objects present in the original binarized localization maps for P2Y~11~. This method only detects objects that are 100% overlapping with each other in two independent images (e.g localization maps for P2Y~11~ and Ca~V~1.2). Random simulation of image pairs for P2Y~11~ and Ca~V~1.2 or P2Y~11~ and PKA~cat~ were generated based on the original super-resolution localization maps for each pair of proteins using the Coste's randomization algorithm included in the JACoP plug-in in ImageJ ([@bib9]) from six different cells per condition. Parameters for the Coste's randomization algorithm were selected to generate simulated images with relative similar cluster size and density to those observed in the original super-resolution localization maps for each protein. Each randomized image was generated after undergoing 1000 randomization rounds. Randomized images were binarized prior to analysis and the percentage of complete P2Y~11~ overlap from the randomized image pairs was calculated as described above.

Cell culture, transfection of tsA-201 cells, and reverse permeabilization {#s4-11}
-------------------------------------------------------------------------

tsA-201 were obtained from Sigma-Aldrich (cat\#: ECACC 96121229). These cells are included in the European Collection of Authenticated Cell Cultures. tsA-201 cells were cultured in DMEM supplemented with 1X pyruvate, 1X glutamax, 8% fetal bovine serum (FBS) and 5 mM glucose (without phenol red) at 37° C in a 5% CO~2~ incubator. Cells were transfected at 60--70% confluence with human P2Y~11~ tagged with GFP at C-terminus (UMR cDNA Resource Center - [www.cDNA.org](http://www.cDNA.org); clone ID P2Y1100000) with JetPRIME transfection reagent (Polyplus transfection SA, NY) for approximately 36 hr. P2Y~11~ sense and antisense oligodeoxynucleotides (ODNs; 2 µM; Integrated DNA Technologies) were transfected in tsA-201 cells 24 hr after initial transfection with P2Y~11~-GFP. The cells were gently washed with 1X PBS and then removed with a cell scrapper using a RIPA lysis buffer solution composed of 50 mM Tris base, 150 mM NaCl, 5 mM EGTA, 10 mM EDTA, 1% nonyl phenoxypolyethoxylethanol-40 (NP-40), 10% glycerol, 0.05% sodium dodecyl sulfate (SDS), 0.4% deoxycholic acid (DOC) with protease inhibitors (1 µg/mL pepstatin A, 10 µg/mL leupeptin, and 20 µg/mL aprotinin). Antisense and sense ODNs for P2Y~11~ were designed and checked for specificity using Prime BLAST against the human P2Y~11~ sequence (NC_000019.10). The sequences used for the antisense ODNs were as follows: 5'-CAAGGCCACCCTAACCACTG-3' and 5'-CTCTCCCTTCCCTGCGTTA-3'. The sequences for sense ODNs were 5'-CAACGTCTCGGGTAAGGAGAA-3' and 5'-ATGAGGAAGGAAACGTGGGT-3'. For all ODNs, the last three bases on the 3' end were phosphorothioated to reduce degradation by cellular nucleases. ODNs were dissolved in nuclease-free water to a 1 mM concentration.

Human adipose arteries were permeabilized in a solution containing (in mM): 120 KCl, 2 MgCl~2~, 10 EGTA, 5 Na~2~ATP, 20 TES (2-\[(2-Hydroxy-1, 1-bis(hydroxymethyl)ethyl)amino\] ethanesulfonic acid, N-\[Tris(hydroxymethyl)methyl\]−2-aminoethanesufonic acid), pH adjusted to 6.8 with NaOH. Arteries were first incubated in permeabilization solution for 20 min at 4°C, followed by a 4 hr incubation at 4°C in a solution supplemented with ODNs (2 µM). Arteries were placed in an ODN-containing solution with elevated MgCl~2~ (10 mM) for 1 hr at room temperature. Permeabilization was reversed by incubating arteries for 30 min at room temperature in MOPS physiological solution composed of (in mM): 140 NaCl, 5 KCl, 10 MgCl~2~, 5 D-glucose, and 2 MOPS, pH adjusted to 7.1 with NaOH. Arteries were incubated in a MOPS solution containing 0.01, 0.1, and 1.8 mM CaCl~2~ in 15 min intervals, increasing Ca^2+^ gradually. After completing reverse permeabilization, arteries were cultured in D-MEM/F-12 culture media supplemented with L-glutamine (2 mM) for 2.5 days at 37°C. Arteries were then lysed and used for Western blot (see Immunoblotting section).

Adenovirus infection of unpassaged arterial myocytes and Fluorescence Resonance Energy Transfer (FRET) {#s4-12}
------------------------------------------------------------------------------------------------------

Laminin (Life Technologies, Grand Island, NY) diluted 100x in sterile-filtered PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na~2~HPO~4~, 1.8 mM KH~2~PO~4~, pH = 7.4) was used to coat \#0 glass coverslips (Karl Hecht, Sondheim, Germany). After adding diluted laminin (100 µL per coverslip), coverslips were placed in a 37° C incubator with 5% CO~2~ for a minimum of 2 hr, then moved to 24-well plate wells (Falcon, Tewksbury, MA), and washed 3x with sterile-filtered PBS. Freshly dissociated human adipose arterial myocytes and mouse aortic cells were plated on the laminin-coated coverslips with 500 μL of serum-containing media for 48 hr in a 37° C incubator with 5% CO~2~. Media was then replaced with 500 μL of serum-free media-containing virus coding for the membrane-targeted Epac1-camps-based FRET sensor (ICUE3-PM) ([@bib2]; [@bib49]) and placed at 37° C with 5% CO~2~ for another 36 hr. Viruses were produced using the AdEasy system (Qbiogene, Carlsbad, CA) ([@bib51]). After infection, media was changed to serum-free media without virus. Glass coverslips were transferred to glass bottom culture dishes (MatTek, Ashland, MA) containing 3 mL PBS at room temperature.

A Zeiss AXIO Observer A1 inverted fluorescence microscope (San Diego, CA) equipped with a Hamamatsu Orca-Flash 4.0 digital camera (Bridgewater, NJ) and controlled by Metaflor software (Molecular Devices, Sunnyvale, CA) acquired phase contrast, CFP480, and FRET images. Phase contrast and CFP480 images were collected with 20x and 40x oil immersion objective lenses, while FRET images were collected using only the 40x oil immersion objective lens. Images for FRET analysis were recorded by exciting the donor fluorophore at 430--455 nm and measuring emission fluorescence with two filters (475DF40 for cyan and 535DF25 for yellow). Images were subjected to background subtraction and acquired every 30 s with exposure time of 200 ms for each channel. The donor/acceptor FRET ratio was calculated and normalized to the ratio value of baseline. CFP480 images were acquired by exciting the donor fluorophore at 430--455 nm and measuring emission fluorescence with the 475DF40 filter for 25 ms. Averages of normalized curves and maximal response to stimulation were graphed based on FRET ratio changes. Binding of cAMP to ICUE3-PM led to decreases in the YFP/CFP ratio, indicating increases in cAMP levels.

Chemicals and statistics {#s4-13}
------------------------

All chemical reagents were from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. Data were analyzed using GraphPad Prism software and expressed as mean ±SEM. Data were assessed for potential outliers using the GraphPad Prism Outlier Test and for normality of distribution using appropriate tests. Statistical significance was then determined using suitable paired or unpaired Student's *t*-test, nonparametric tests or One-way analysis of variance (ANOVA) for multiple comparisons with proper post hoc test. p\<0.05 was considered statistically significant (denoted by \* in figures).
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Thank you for submitting your article \"A G~s~-coupled purinergic receptor boosts Ca^2+^ influx and vascular excitability during diabetic hyperglycemia\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, including Richard S Lewis as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Richard Aldrich as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Mark T Nelson (Reviewer \#2). A further reviewer remains anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Cardiovascular complications of diabetes arise from augmented vasoconstriction of arterial myocytes in response to elevated glucose. In this manuscript, Navedo and colleagues demonstrate a pivotal role for the Gs- coupled metabotropic purinergic receptor, P2Y~11~, in mediating the vasoconstrictor response to glucose in mouse and human vascular smooth muscle myocytes. Using molecular, pharmacological/functional and FRET-based approaches, the authors provide evidence that P2Y~11~ is expressed in mouse and human vascular smooth muscle cells, and that glucose causes vasoconstriction through a cascade involving ATP release, P2Y~11~ activation, cAMP synthesis, and PKA-dependent phosphorylation of Ca~V~1.2. In support of the PKA-dependent activation of Ca~V~1.2 and subsequent vasoconstriction, they show using proximity analyses that a subpopulation of P2Y~11~ is in close proximity to PKA and Ca~V~1.2. The signaling specificity afforded by such microdomains may explain the paradoxical vasoconstriction-promoting effect of PKA, which is generally associated with vasodilatory responses through effects on K^+^ channels. The role of P2Y~11~ is convincing and is a major new insight. Also significant is the identification of smooth muscle P2Y~11~ as a potential target in the management of diabetic vasculopathy.

Essential revisions:

1\) There were concerns about whether the glucose responses are affected by possible changes in osmolarity. From the Materials and methods, it does not appear that changes in osmolarity were controlled for, and the effect of glucose may be different in hypertonic and isotonic conditions. A series of controls for all experiments should be included in the manuscript rather than referencing an abstract (Syed et al., 2018).

2\) Antibodies need to be validated and quantification described in more detail.a) For assessing Ser^1928^ phosphorylation, showing full-length blots with only a single molecular weight does not demonstrate specificity. The method of quantifying band densities should be described in more detail (more than just saying ImageJ was used). Were band densities integrated, and how were doublets quantified (e.g., Figures 1, 6, and especially Figure 7C)? In Figure 7C, MW markers are needed; is the upper Cav band of the doublet phosphorylated, and could this be used to estimate the proportion of channels that are phosphorylated? It is difficult to assess the linearity of the antibody without showing on the same blot dephosphorylated channels and fully phosphorylated channels. Does a 30% increase mean 30% of the channels are phosphorylated?

b\) Primary antibodies to P2Y~11~ and PKA~cat~ need to be validated. It appears that P2Y~11~ ab is not specific for P2Y~11~ in mouse (extra bands in Figure 2---figure supplement 1A). This is important because the only evidence that P2Y~11~ is expressed in arterial myocytes comes from cell staining (Figure 2); the Westerns are from lysates also containing endothelial cells which are known to express P2Y~11~.

3\) While ATP might be expected to accumulate in restricted spaces in tissue to activate P2Y~11~, there is some doubt about whether ATP release could be responsible for the increased Ba2+ currents in patch-clamp experiments where ATP would be free to diffuse. More evidence should be provided to support the role of ATP. For example, does continuous bath perfusion reduce or eliminate the increase in Ba2+ current in response to glucose? Can ATP release be detected by luciferase in the bath (e.g., see Ospichuk and Cahalan, Nature 359:241, 1992)? Finally, please discuss possible mechanisms of ATP secretion and what is known about the affinity of P2Y11 for ATP.

4\) To show that phosphorylation of Ser^1928^ is essential for the regulation of contractility by P2Y~11~ agonists (and not merely correlated), vasoconstriction measurements (Figure 7) should be repeated with a S1928A knockin mouse. Similarly, the single-channel Po (Figure 8) should also be measured in the knockin animals to counter the possibility that prolonged incubation in glucose may have increased Po by affecting other signaling pathways and gene expression.

5\) The specificity of LTCC modulation by glucose is an important issue, and the GSD data as they stand are rather descriptive and do not establish whether P2Y~11~ exists in complexes with AC, PKA, and LTCC. While it is beyond the scope of this paper to establish the composition of a P2Y~11~ signaling complex, the existence of such a complex would make the distribution of P2Y~11~, PKA, and Ca~V~1.2 non-random. To address this point, experimentally observed results should be compared with those of a simulated random distribution of the proteins at the same overall density, and the results shown in a supplementary figure.

6\) Figures 4 and 5: The FRET response (cAMP production) is about twice as large in human myocytes than in mouse myocytes (normalized FRET ratio change, \~0.1 vs. \~0.05), despite the fact that the density of P2Y~11~-Ca~V~1.2 clusters in human myocytes is about 20% that in mouse myocytes (\~0.03/µm2 vs. \>0.15/µm2) and P2Y~11~-PKA cluster density is about the same in both humans and mice (\~0.06/µm2). Why is cAMP production noticeably higher in humans than in mice, and is this difference significant? Please provide comment in the text.

7\) A microdomain containing P2Y~11~, Ca~V~1.2, PKA and AC5 is discussed in the Discussion, but no data are shown for a role of AC5, only a citation of a FASEB meeting abstract (Discussion, first paragraph; Syed et al., 2018). Ideally, these data should be included in the current manuscript.

8\) In the last paragraph of the subsection "The P2Y~11~ inhibitor NF340 prevents glucose-induced Ser^1928^ phosphorylation, LTCC activity and vasoconstriction", the NF546 experiment does not rule out involvement of P2Y~1~ receptor, it merely shows it is not necessary for the vasoconstriction. To show it does not contribute, the authors should add the inhibitor after glucose to see if it inhibits (Figure 6---figure supplement 1D).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A G~s~-coupled purinergic receptor boosts Ca^2+^ influx and vascular excitability during diabetic hyperglycemia\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Richard Aldrich (Senior Editor) and a Reviewing Editor.

The manuscript has been improved and the reviewers\' comments have been addressed well with new experimental data and additions to the text. However, several points need to be explained more clearly before the manuscript can be accepted, as outlined below:

Point 1. Please show a bar graph quantifying the pSer Western in Figure 1---figure supplement 1E (like that shown in Figure 1C) to make the point.

Point 2b. Please show two MW markers (55, 35) for the P2Y~11~ blot in Figure 2---figure supplement 1D since the band is well below 55 kD. This is needed to show expression at the expected MW of 40 kD.

Point 3. Please describe the perfusion experiment in more detail -- in particular, the speed of perfusion (ml/min), and the time interval between changes in perfusion rate and collection of data. Please state the EC50 for stimulating P2Y~11~ with ATP in the text, with a reference.

Point 5. The simulations and analysis need to be explained in the Materials and methods section. How is \"overlap\" quantified in Figure 3I? It is surprising that almost no overlap is visible in the experimental data in Figure 3---figure supplement 3C (\"overlap\" panel). Briefly describe how was randomization done and how many times it was repeated. The explanation in the second paragraph of the subsection "P2Y~11~ receptors are in close proximity to Ca~V~1.2 and PKA~cat~ in arterial myocytes" does not adequately explain how the simulation was done, and what we are looking at in the images in Figure 3---figure supplement 3C.

10.7554/eLife.42214.074

Author response

> Essential revisions:
>
> 1\) There were concerns about whether the glucose responses are affected by possible changes in osmolarity. From the Materials and methods, it does not appear that changes in osmolarity were controlled for, and the effect of glucose may be different in hypertonic and isotonic conditions. A series of controls for all experiments should be included in the manuscript rather than referencing an abstract (Syed et al., 2018).

To address the concerns regarding possible osmolarity effects, we performed experiments using equimolar concentrations of the nonpermeable mannitol (20 mM mannitol = 10 mM D-glu + 10 mM mannitol). Our new data show that elevated mannitol failed to induce vasoconstriction as well as to potentiate L-type Ca~V~1.2 channel (LTCC) activity, increase phosphorylation of Ca~V~1.2 at serine 1928 (Ser^1928^) or stimulate cAMP production in arterial myocytes. These results suggest that effects observed in cAMP synthesis, Ser^1928^ phosphorylation, LTCC activity and vascular reactivity in response to an increase in extracellular glucose (e.g. 20 mM D-glu) are not due to osmolarity effects but are rather a direct consequence of elevated glucose. These data are consistent with previous studies from our group and others (Jackson et al., 2016; Navedo et al., 2010; Nystoriak et al., 2014; Nystoriak et al., 2017; Rainbow et al., 2006). Moreover, the new data are in line with our recent observations indicating that the elevated glucose effects on LTCC activity and vascular reactivity require glucose internalization and metabolic utilization (Nystoriak et al., 2017). These new data and discussion are now included as Figure 1---figure supplement 1B, 1C and 1E (subsection "Glucose-induced extracellular nucleotide release mediates Ser^1928^ phosphorylation, increased LTCC activity and vasoconstriction", first, second and third paragraphs), Figure 5---figure supplement 1B and 1C (subsection "Increased sarcolemmal cAMP synthesis in arterial myocytes in response to a P2Y~11~ agonist recapitulates glucose effects", last paragraph) and Figure 8A and 8B (subsection "Increased Ser^1928^ phosphorylation and LTCC activity during chronic diabetic hyperglycemia are prevented by a P2Y~11~ inhibitor").

> 2\) Antibodies need to be validated and quantification described in more detail.a) For assessing Ser^1928^ phosphorylation, showing full-length blots with only a single molecular weight does not demonstrate specificity.

We appreciate this comment and apologize for not addressing the specificity of the antibodies clearly in our original manuscript. The specificity of the phospho-specific antibody for Ser^1928^ as well as the FP1 antibody for total Ca~V~1.2 measurement has been extensively and thoroughly validated in multiple published studies by our group, including for use in arterial myocytes (Buonarati et al., 2017; Hall et al., 2013; Nystoriak et al., 2017; Patriarchi et al., 2016). Importantly, immunoreactivity at 250 kDa of Ca~V~1.2 with the phospho-specific antibody for Ser^1928^ (but not a phospho-specific antibody for Ser^1700^) and FP1 are completely eliminated in tissue from S1928A KI mice (Figure 3 in Patriarchi et al., 2016) and conditional Ca~V~1.2 KO mice (Figure 2 in Buonarati et al., 2017), respectively. Full blots are shown in Buonarati et al., 2017, although the 100 kDa marker had been run to the bottom of the gel for better resolution of the high molecular mass Ca~V~1.2. Blotted membranes were trimmed to save on the use of these antibodies, which are generated in-house and only available in limited quantity. We have modified the original text to clarify this issue (subsection "Glucose-induced extracellular nucleotide release mediates Ser^1928^ phosphorylation, increased LTCC activity and vasoconstriction", third paragraph; subsection "P2Y~11~ receptors are in close proximity to Ca~V~1.2 and PKA~cat~ in arterial myocytes", second paragraph).

> The method of quantifying band densities should be described in more detail (more than just saying ImageJ was used). Were band densities integrated, and how were doublets quantified (e.g., Figures 1, 6, and especially Figure 7C)?

We apologize for this oversight. We have revised the Materials and methods section of our manuscript to include an expanded description on quantification of Western blot data (see subsection "Immunoprecipitation and immunoblotting").

> In Figure 7C, MW markers are needed.

Thank you for pointing this out. We have added MW markers to all our blots in the main and supplementary figures.

> Is the upper Cav band of the doublet phosphorylated, and could this be used to estimate the proportion of channels that are phosphorylated?

The upper band represents the full length form of Ca~V~1.2, which harbors Ser^1928^ (Hell et al., 1993). The lower band represents a shorter Ca~V~1.2 form that is truncated around residue 1800 and thus does not contain Ser^1928^. Accordingly, only the upper band can be phosphorylated on Ser^1928^. The shorter channel form still has the proteolytically cleaved C-terminal domain attached to it, but this C-terminal fragment is difficult to detect with the small amounts of material from our arterial samples.

To define basal Ser^1928^ phosphorylation levels, we previously used Ca~V~1.2 isolated from rat forebrain where we obtain much more material than from our arterial samples. There, we estimated that \~16.7% of the Ca~V~1.2 long form is phosphorylated on Ser^1928^ under basal conditions in healthy adult rats (Davare and Hell, 2003). However, this is only an upper limit. With our arterial preparation (freshly isolated small resistance arteries from cerebral and mesenteric vessels) and the small amount of working material obtained from it, it could be less than that because the only way we can obtain such an estimate is by comparing the immunoblot signal from Ca~V~1.2 from untreated samples with those where Ca~V~1.2 had been incubated after the immunoprecipitation with purified PKA and Mg-ATP. The estimate assumes that all full-length Ca~V~1.2 is phosphorylated on Ser^1928^ under these stimulatory conditions, but unfortunately, we cannot be completely certain about this. Hence, we will not be able to determine with high confidence the percentage of total Ca~V~1.2 that is phosphorylated at Ser^1928^ under basal conditions in our preparation. Such a number would also not necessarily be too helpful because a substantial fraction of Ca~V~1.2 resides inside the cells (Conrad et al., 2018; Ghosh et al., 2018) when only channels at the plasma membrane are relevant for potentiation by Ser^1928^ phosphorylation. For instance, if we would find that \~16% of Ca~V~1.2 is phosphorylated in arterial lysates under basal conditions, it could quite well reflect that 50% of Ca~V~1.2 at the surface membrane are Ser^1928^ phosphorylated if the intracellular pool constitutes 70% of total Ca~V~1.2 and is largely not phosphorylated. We will be working in future studies to address this interesting point in a rigorous manner but would like to respectfully note that these data will not change the conclusions of the present study.

> It is difficult to assess the linearity of the antibody without showing on the same blot dephosphorylated channels and fully phosphorylated channels.

We show dephosphorylated and phosphorylated channels on the same blot -- e.g. total Ca~V~1.2 reprobed after Ser^1928^ phosphorylation probe. Moreover, our blots are analyzed after films are exposed for increasing time periods (1 min, 2 min, 4 min) to ensure that the signals are in the linear range, as detailed in our previous work (Davare and Hell, 2003; Hall et al., 2006). This information is clarified and expanded in our revised manuscript (subsection "Immunoprecipitation and immunoblotting").

> Does a 30% increase mean 30% of the channels are phosphorylated?

No. It means the percentage of channels that were phosphorylated has increased by 30%. As an example, if 10% of the channels are phosphorylated basally and treatment increases the phosphorylation state by 30%, then \~13% of the channels would be phosphorylated upon treatment.

> b\) Primary antibodies to P2Y~11~ and PKA~cat~ need to be validated. It appears that P2Y~11~ ab is not specific for P2Y~11~ in mouse (extra bands in Figure 2---figure supplement 1A). This is important because the only evidence that P2Y~11~ is expressed in arterial myocytes comes from cell staining (Figure 2); the Westerns are from lysates also containing endothelial cells which are known to express P2Y~11~.

To address this question, we performed additional experiments. The PKA~cat~ Ab was validated using a blocking peptide provided by the vendor (Santa Cruz Biotechnology). Briefly, immunofluorescent labeling of PKA~cat~ in arterial myocytes was performed using a mouse anti-PKA~cat~ Ab (Santa Cruz Biotechnology) incubated with or without a PKA~cat~ blocking peptide (A-2; Santa Cruz Biotechnology) before applying to cells on coverslips. Consistent with a previous study from our group (Nystoriak et al., 2017), arterial myocytes showed broad intracellular PKA~cat~-associated fluorescence, which was completely lost when the PKA~cat~ Ab was preabsorbed with the PKA~cat~ blocking peptide. These data are now presented in Figure 3---figure supplement 1 (subsection "P2Y~11~ receptors are in close proximity to Ca~V~1.2 and PKA~cat~ in arterial myocytes", second paragraph) of the revised manuscript.

As for the P2Y~11~ Ab validation, we performed multiple tests. First, we detected single protein bands of expected molecular weight in lysates from untransfected and vehicle treated tsA-201 cells, which are known to endogenously express P2Y~11~ (Dreisig and Kornum, 2016). When tsA-201cells were transfected with a vector encoding a P2Y~11~ tagged with GFP (P2Y~11~-GFP), two bands were detected. The small molecular weight band corresponds to the endogenous P2Y~11~ and the other band is consistent with the addition of GFP to P2Y~11~ (see Figure 2A). Treatment of tsA-201 cells over-expressing P2Y~11~-GFP with specific P2Y~11~ antisense oligodeoxynucleotides (ODNs) resulted in a reduction in the intensity of both bands (Figure 2B). In native arterial tissue, we detected an immunoreactive band of the expected molecular weight for P2Y~11~ (\~40 kDa) with the same P2Y~11~ Ab (Figure 2C and Figure 2---figure supplement 1A). Importantly, the abundance of this \~40 kDa band was reduced to about \~50% of the basal P2Y~11~ protein abundance in arteries treated with specific P2Y~11~ antisense ODNs (Figure 2---figure supplement 1B). A band of \~110-120 kDa was observed in mouse arterial lysates, perhaps reflecting the formation of heterodimers between the P2Y~11~ receptor itself or other purinergic/ G protein-coupled receptors, as previously reported (Barragan-Iglesias et al., 2015; Barragan-Iglesias et al., 2014; Ecke et al., 2008; Nishimura et al., 2016). This discussion is included in the first paragraph of the subsection "P2Y~11~ receptors are in close proximity to Ca~V~1.2 and PKA~cat~ in arterial myocytes" We also observed a band of expected molecular weight for P2Y~11~ in lysates from [isolated mouse arterial myocytes]{.ul} (Figure 2---figure supplement 1D), and P2Y~11~-associated fluorescence was not detected in isolated mouse arterial myocytes exposed to a boiled P2Y~11~ Ab (Figure 2---figure supplement 1E). In addition, note that the functional expression of human P2Y~11~ and mouse P2Y~11~-like receptors in arterial myocytes is further supported by multiple well-controlled functional studies described throughout the manuscript (please see Figures 5-8). Finally, we reached out to several commercial companies that sell P2Y~11~ Ab to obtain antigenic peptides for P2Y~11~. They do not have available antigenic peptides for P2Y~11~ Ab nor were able to provide us with the amino acid sequence used to raise the antibody, thus prohibiting that additional approach to antibody validation. Regardless, we consider that our multiple biochemical and functional approaches provide strong support for validation of the P2Y~11~ Ab and the presence of human P2Y~11~ and mouse P2Y~11~-like receptor in arterial myocytes.

> 3\) While ATP might be expected to accumulate in restricted spaces in tissue to activate P2Y~11~, there is some doubt about whether ATP release could be responsible for the increased Ba2+ currents in patch-clamp experiments where ATP would be free to diffuse. More evidence should be provided to support the role of ATP. For example, does continuous bath perfusion reduce or eliminate the increase in Ba2+ current in response to glucose? Can ATP release be detected by luciferase in the bath (e.g., see Ospichuk and Cahalan, Nature 359:241, 1992)? Finally, please discuss possible mechanisms of ATP secretion and what is known about the affinity of P2Y11 for ATP.

We recognize that our original cartoon identifying extracellular ATP as a primary mediator of glucose-induced activation of P2Y~11~ was premature. Although we are now including additional data showing that the well-known non-hydrolyzed ATP analog and P2Y~11~ agonist ATPγS (von Kugelgen and Harden, 2011) stimulates Ba^2+^ currents in arterial myocytes (Figure 7---figure supplement 1B; subsection "The P2Y~11~ agonist NF546 stimulates Ser^1928^ phosphorylation, PKA-dependent LTCC activity and vasoconstriction", first paragraph), we have modified the illustration to avoid data overinterpretation.

Note, however, that increased glucose (20 mM D-glucose) has been shown to trigger the release of NUC into the extracellular space of many cells, including arterial myocytes (Costa et al., 2009; Hazama et al., 1998; Nilsson et al., 2006; Parodi et al., 2002). Our results with apyrase support this conclusion (Figure 1). In addition, we now provide additional data to support the concept that glucose-induced extracellular nucleotide release mediates the changes in Ba^2+^ current in isolated voltage clamped arterial myocytes by performing the proposed experiments with continuous bath perfusion. Accordingly, we were able to record robust Ba^2+^ current in isolated voltage clamped arterial myocytes under static and flow conditions. However, as predicted by the reviewers, whereas I~Ba~ recorded in a static bath was significantly elevated upon increasing external D-glucose from 10 mM to 20 mM, this response was not observed under continuous flow conditions. These results suggest that nucleotides (NUC) could indeed diffuse away under continuous flow conditions, whereas they could accumulate in or around the area of release at the surface membrane of arterial myocytes to induce the optimal activation of the signaling pathway underlying the increased Ba^2+^ current density in response to 20 mM D-glucose. We did attempt to detect glucose-induced NUC release (e.g. ATP) using a commercially available luciferin-luciferase kit. Unfortunately, we could not detect any signal. After consulting with the manufacturer, this was attributed to a need for optimizing the preparation to detect NUC release from native arterial myocytes. This is not a trivial task and may take more time than that allotted for resubmission of the manuscript. We are currently working to optimize our preparation/assay and rigorously address this point in a comprehensive follow up study. However, new data provide further support to our hypothesis that elevated glucose evokes LTCC activity and vasoconstriction through an autocrine mechanism involving secreted nucleotides, which are well-known activators of G-coupled P2Y receptors (von Kugelgen and Harden, 2011). These new data and discussion are now included as Figure 1---figure supplement 3 (subsection "Glucose-induced extracellular nucleotide release mediates Ser^1928^ phosphorylation, increased LTCC activity and vasoconstriction").

As suggested, we provide a discussion of possible mechanisms of NUC (including ATP) secretion and P2Y~11~ pharmacological profile (see Discussion, sixth paragraph).

> 4\) To show that phosphorylation of Ser^1928^ is essential for the regulation of contractility by P2Y~11~ agonists (and not merely correlated), vasoconstriction measurements (Figure 7) should be repeated with a S1928A knockin mouse. Similarly, the single-channel Po (Figure 8) should also be measured in the knockin animals to counter the possibility that prolonged incubation in glucose may have increased Po by affecting other signaling pathways and gene expression.

To address this question, we performed additional experiments. First, we found that arteries from S1928A mice failed to constrict in response to the P2Y~11~ agonist NF546. These results are in stark contrast to those observed for wild type arteries (see Figure 7E and 7F), and further support the conclusion that phosphorylation of Ser^1928^ is essential for the regulation of vascular reactivity in response to a P2Y~11~ agonist. These new data and discussion are now included as Figure 7F in the revised manuscript (subsection "The P2Y~11~ agonist NF546 stimulates Ser^1928^ phosphorylation, PKA-dependent LTCC activity and vasoconstriction", last paragraph).

Second, we performed the suggested single-channel experiments in arterial myocytes from S1928A mice under chronically elevated glucose stimulation (48 hours). Results indicate that S1928A cells isolated from either 10 mM and 20 mM D-glucose groups had similar LTCC open probability (nP~o~), which are comparable to that observed for LTCCs in wild type cells isolated from the group treated with 10 mM D-glucose. These results counter the possibility that prolonged incubation in elevated glucose may have increased LTCC nP~o~ by affecting other signaling pathways and gene expression, and further support a key role for Ser^1928^ phosphorylation in regulation of LTCC activity during diabetic hyperglycemia. These new data and discussion are now included as Figure 8---figure supplement 1B (subsection "Increased Ser^1928^ phosphorylation and LTCC activity during chronic diabetic hyperglycemia are prevented by a P2Y~11~ inhibitor") in the revised manuscript.

> 5\) The specificity of LTCC modulation by glucose is an important issue, and the GSD data as they stand are rather descriptive and do not establish whether P2Y~11~ exists in complexes with AC, PKA, and LTCC. While it is beyond the scope of this paper to establish the composition of a P2Y~11~ signaling complex, the existence of such a complex would make the distribution of P2Y~11~, PKA, and Ca~V~1.2 non-random. To address this point, experimentally observed results should be compared with those of a simulated random distribution of the proteins at the same overall density, and the results shown in a supplementary figure.

To address this point, we performed the suggested comparison between experimental and simulated random protein distribution. Accordingly, we compared the frequency of P2Y~11~-Ca~V~1.2 and P2Y~11~-PKA overlap that was obtained experimentally with that from simulated images that were randomized for proteins of interest at the same overall density as those observed in the experimental super-resolution maps (Bolte and Cordelieres, 2006). The analysis revealed a higher level of overlap between P2Y~11~-Ca~V~1.2 and P2Y~11~-PKA in the experimental data than that observed for a simulated random distribution. These results suggest a selective and distinctive interaction between a subpopulation of P2Y~11~ and a pool of Ca~V~1.2 and PKA, which complements our super-resolution data in the first submission. These new data and discussion are now included as Figure 3I and Figure 3---figure supplement 3C (subsection "P2Y~11~ receptors are in close proximity to Ca~V~1.2 and PKAcat in arterial myocytes", second paragraph) in the revised manuscript.

> 6\) Figures 4 and 5: The FRET response (cAMP production) is about twice as large in human myocytes than in mouse myocytes (normalized FRET ratio change, \~0.1 vs. \~0.05), despite the fact that the density of P2Y~11~-Ca~V~1.2 clusters in human myocytes is about 20% that in mouse myocytes (\~0.03/µm2 vs. \>0.15/µm2) and P2Y~11~-PKA cluster density is about the same in both humans and mice (\~0.06/µm2). Why is cAMP production noticeably higher in humans than in mice, and is this difference significant? Please provide comment in the text.

To answer this question, we first respectfully submit that it would not be appropriate at this time to correlate PLA data with the FRET responses as many factors may independently influence each measurement. The PLA data indicate relative abundance of the protein complex whereas the FRET data indicate relative signaling intensity after stimulation. There is not a necessary correlation between these two results. Accordingly, the goal of our PLA experiments is to define close association between P2Y~11~-Ca~V~1.2 and P2Y~11~-PKA, whereas the goal of the FRET experiments is to determine whether glucose could modulate cAMP signaling as well as define potential mechanisms such as the involvement of the P2Y~11~. We strongly believe that our data have accomplished these goals.

The cAMP production in response to glucose and the P2Y~11~ agonist NF546 is indeed significantly larger in human arterial myocytes compared to mouse cells (*P* \< 0.05). The reasons for this are currently unclear but may include intrinsic differences associated with species (human vs. mouse), blood vessels (human adipose arteries vs mouse aortae) and expression patterns of the biosensor in human vs. mouse cells, as well as variations in protein expression and receptor/enzyme activity (e.g. P2Y~11~, AC and PDE expression/activity) in human vs. mouse arterial myocytes. Whether either or all of the factors described above contribute to distinctive cAMP responses in human vs mouse arterial myocytes as well as their physiological implications, remain to be explored. Nevertheless, as suggested, we now provide a description of these issues in the revised manuscript (subsection "Increased sarcolemmal cAMP synthesis in arterial myocytes in response to a P2Y~11~ agonist recapitulates glucose effects", last paragraph).

> 7\) A microdomain containing P2Y~11~, Ca~V~1.2, PKA and AC5 is discussed in the Discussion, but no data are shown for a role of AC5, only a citation of a FASEB meeting abstract (Discussion, first paragraph; Syed et al., 2018). Ideally, these data should be included in the current manuscript.

We recognize that our discussion of AC5 in complex withP2Y~11~, Ca~V~1.2 and PKA is premature. We have therefore modified the text as reference to AC5 does not directly relate to the focus of this manuscript. We are working to rigorously and comprehensively examine the role of AC5 in a follow up manuscript.

> 8\) In the last paragraph of the subsection "The P2Y~11~ inhibitor NF340 prevents glucose-induced Ser^1928^ phosphorylation, LTCC activity and vasoconstriction", the NF546 experiment does not rule out involvement of P2Y~1~ receptor, it merely shows it is not necessary for the vasoconstriction. To show it does not contribute, the authors should add the inhibitor after glucose to see if it inhibits (Figure 6---figure supplement 1D).

To address this question, we performed additional experiments. We now show that glucose-mediated vasoconstriction is not affected by adding the P2Y~1~ inhibitor MRS2179 either before or after 20 mM D-glucose. These new data and discussion are now included as Figure 6---figure supplement 1E (subsection "The P2Y~11~ inhibitor NF340 prevents glucose-induced Ser^1928^ phosphorylation, LTCC activity and vasoconstriction", last paragraph) in the revised manuscript.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved and the reviewers\' comments have been addressed well with new experimental data and additions to the text. However, several points need to be explained more clearly before the manuscript can be accepted, as outlined below:
>
> Point 1. Please show a bar graph quantifying the pSer Western in Figure 1---figure supplement 1E (like that shown in Figure 1C) to make the point.

A bar plot quantifying pSer^1928^ in the presence of 10 mM D-glucose and 20 mM mannitol is now included in the revised version of the manuscript (Figure 1---figure supplement 1E).

> Point 2b. Please show two MW markers (55, 35) for the P2Y~11~ blot in Figure 2---figure supplement 1D since the band is well below 55 kD. This is needed to show expression at the expected MW of 40 kD.

As requested, we now show two MW marker for the WB blot in Figure 2---figure supplement 2D.

> Point 3. Please describe the perfusion experiment in more detail -- in particular, the speed of perfusion (ml/min), and the time interval between changes in perfusion rate and collection of data. Please state the EC~50~ for stimulating P2Y~11~ with ATP in the text, with a reference.

We have expanded our description of the perfusion experiments and have provided additional information about time intervals between perfusion rate and collection of data in the Materials and methods section and in the figure legend of the revised manuscript (subsection "Electrophysiology", first paragraph and Figure 1---figure supplement 2 legend). We also stated the EC~50~ for stimulating P2Y~11~ with ATP and have provided citations for this in the revised manuscript (subsection "The P2Y~11~ agonist NF546 stimulates Ser^1928^ phosphorylation, PKA-dependent LTCC activity and vasoconstriction", first paragraph, and Discussion, sixth paragraph).

> Point 5. The simulations and analysis need to be explained in the Materials and methods section. How is \"overlap\" quantified in Figure 3I? It is surprising that almost no overlap is visible in the experimental data in Figure 3---figure supplement 3C (\"overlap\" panel). Briefly describe how was randomization done and how many times it was repeated. The explanation in the second paragraph of the subsection "P2Y~11~ receptors are in close proximity to Ca~V~1.2 and PKA~cat~ in arterial myocytes" does not adequately explain how the simulation was done, and what we are looking at in the images in Figure 3---figure supplement 3C.

To address these points, we have expanded the description of the generation of simulation/randomization data as well as the overall analysis in the revised manuscript. Randomization of P2Y~11~-Ca~V~1.2 and P2Y~11~-PKA~cat~ was repeated six times and then compared against experimental data obtained from the super-resolution localization maps. The percentage of P2Y~11~ overlap was determined by multiplying thresholded, binary localization maps (experimental and simulated data) of P2Y~11~by those from Ca~V~1.2 or PKA~cat~. We apologize and acknowledge that the quality of original images in Figure 3---figure supplement 3C was not adequate, thus preventing proper evaluation of the data. We have modified the presentation of these images by changing the LUT to an inverted grayscale LUT that makes the overlapping signals more apparent and therefore, better reflects the results from the amalgamated data. Changes are found in subsection "P2Y~11~ receptors are in close proximity to Ca~V~1.2 and PKA~cat~ in arterial myocytes", second paragraph, subsection "Immunolabeling and Ground State Depletion (GSD) microscopy", last paragraph, and in the Figure 3---figure supplement 3 legend.

[^1]: These authors contributed equally to this work.
